|
|
| Zeile 1: |
Zeile 1: |
| − | {{bibi|TI=Mg - QTc|S1=%22mg2%2B%22+OR+magnesium+OR+mgso4+OR+hypomagnes*+OR+hypermagnes*+OR+trpm7|S2=QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+OR+lqt*+OR+long+qt+OR+early+afterdepolari*+OR+early+after-depolari*+OR+torsade+de+pointes+OR+%22kir2.1%22+OR+%22kv4.2%22+OR+hERG|S3=|dPMID=08/05/20|dPMC=----}}
| |
| − | {{tp|p=22174173|t=2011. A rare electrocardiographic manifestation of a rare form of multiple electrolyte disturbances: hyperparathyroid crisis.|pdf=|usr=}}
| |
| − | {{tp|p=8209703|t=1994. Hepatite aguda alcoolica complicada com arritmia cardiaca. Alcool, hepatite, hipomagnesiemia, torsade de pointes, corticoterapia.|pdf=|usr=}}
| |
| − | {{tp|p=1539780|t=1992. Torsade de pointes and long QT syndrome following major blood transfusion.|pdf=|usr=}}
| |
| − | {{tp|p=24303973|t=2013. Licorice-induced severe hypokalemia with recurrent torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=32389016|t=2020. Torsade de pointes in initiating hemodialysis: a case report.|pdf=|usr=}}
| |
| − | {{tp|p=14666271|t=2003. Female alcoholics: electrocardiographic changes and associated metabolic and electrolytic disorders.|pdf=|usr=}}
| |
| − | {{tp|p=23060109|t=2012. Serum levels of magnesium in sudden cardiac deaths among people with schizophrenia: hit or miss?|pdf=|usr=}}
| |
| − | {{tp|p=21452253|t=2011. Prolonged corrected QT interval in anti-Ro/SSA-positive adults with systemic lupus erythematosus.|pdf=|usr=}}
| |
| − | {{tp|p=25815024|t=2014. Methadone induced torsades de pointes and ventricular fibrillation: A case review.|pdf=|usr=}}
| |
| − | {{tp|p=22947859|t=2012. Multi-ion distributions in the cytoplasmic domain of inward rectifier potassium channels.|pdf=|usr=}}
| |
| − | {{tp|p=20712994|t=2010. Phosphatidylinositol-4,5-bisphosphate (PIP(2)) stabilizes the open pore conformation of the Kv11.1 (hERG) channel.|pdf=|usr=}}
| |
| − | {{tp|p=11566776|t=2001. Unitary conductance variation in Kir2.1 and in cardiac inward rectifier potassium channels.|pdf=|usr=}}
| |
| − | {{tp|p=9788926|t=1998. Interaction of Ba2+ with the pores of the cloned inward rectifier K+ channels Kir2.1 expressed in Xenopus oocytes.|pdf=|usr=}}
| |
| − | {{tp|p=8842207|t=1996. [K+] dependence of open-channel conductance in cloned inward rectifier potassium channels (IRK1, Kir2.1).|pdf=|usr=}}
| |
| − | {{tp|p=31783793|t=2019. Prevalence and risk factors of prolonged corrected QT interval in general Chinese population.|pdf=|usr=}}
| |
| − | {{tp|p=30157775|t=2018. Effect of serum electrolytes within normal ranges on QTc prolongation: a cross-sectional study in a Chinese rural general population.|pdf=|usr=}}
| |
| − | {{tp|p=30999887|t=2019. Associations of serum and dialysate electrolytes with QT interval and prolongation in incident hemodialysis: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study.|pdf=|usr=}}
| |
| − | {{tp|p=27797880|t=2016. Ventricular fibrillation via torsade des pointes of cardiac sarcoidosis with preserved left ventricular ejection fraction.|pdf=|usr=}}
| |
| − | {{tp|p=24121811|t=2013. Overdrive pacing in a patient with incessant torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=22987900|t=2012. Severe primary hypothyroidism presenting with torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=23203174|t=2012. Syncope in a patient being treated for hepatic and intestinal amoebiasis.|pdf=|usr=}}
| |
| − | {{tp|p=32169926|t=2020. Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register-based cohort study.|pdf=|usr=}}
| |
| − | {{tp|p=2467681|t=1989. Electrocardiographic findings and frequency of arrhythmias in Bartter's syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=26183037|t=2016. Pharmacological treatment of acquired QT prolongation and torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=19812810|t=2009. A sweet tooth as the root cause of cardiac arrest.|pdf=|usr=}}
| |
| − | {{tp|p=27212965|t=2016. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management.|pdf=|usr=}}
| |
| − | {{tp|p=29304463|t=2018. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.|pdf=|usr=}}
| |
| − | {{tp|p=22825908|t=2012. QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature.|pdf=|usr=}}
| |
| − | {{tp|p=21660912|t=2011. Electrolyte disorders and arrhythmogenesis.|pdf=|usr=}}
| |
| − | {{tp|p=28357022|t=2012. Failure to Treat Torsades de Pointes.|pdf=|usr=}}
| |
| − | {{tp|p=24428853|t=2014. Antibiotic-induced cardiac arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=18690045|t=2007. Differences between ion binding to eag and HERG voltage sensors contribute to differential regulation of activation and deactivation gating.|pdf=|usr=}}
| |
| − | {{tp|p=32554946|t=2020. Magnesium Deficiency Causes Transcriptional Downregulation of Kir2.1 and Kv4.2 Channels in Cardiomyocytes Resulting in QT Interval Prolongation.|pdf=|usr=}}
| |
| − | {{tp|p=10526691|t=1999. Prolongation of the QT interval in children with liver failure.|pdf=|usr=}}
| |
| − | {{tp|p=9068917|t=1997. A practical approach to torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=7902224|t=1993. Torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=8269653|t=1993. Magnesium and the heart: antiarrhythmic therapy with magnesium.|pdf=|usr=}}
| |
| − | {{tp|p=8416758|t=1993. Abnormal QT intervals associated with negative T waves induced by antiarrhythmic drugs are rapidly reduced using magnesium sulfate as an antidote.|pdf=|usr=}}
| |
| − | {{tp|p=1551265|t=1992. Electrophysiologic and antiarrhythmic effects of magnesium in patients with inducible ventricular tachyarrhythmia.|pdf=|usr=}}
| |
| − | {{tp|p=1660796|t=1991. Acute effects of the ACE inhibitor lisinopril on cardiac electrophysiological parameters of isolated guinea pig hearts.|pdf=|usr=}}
| |
| − | {{tp|p=26251626|t=2015. Serum magnesium concentrations in patients receiving sodium picosulfate and magnesium citrate bowel preparation: an assessment of renal function and electrocardiographic conduction.|pdf=|usr=}}
| |
| − | {{tp|p=26069818|t=2012. Magnesium in disease.|pdf=|usr=}}
| |
| − | {{tp|p=29849428|t=2017. Methadone-induced Torsades de Pointes Masquerading as Seizures.|pdf=|usr=}}
| |
| − | {{tp|p=32670733|t=2020. Magnesium Supplementation Shortens Hemodialysis-Associated Prolonged QT.|pdf=|usr=}}
| |
| − | {{tp|p=22114630|t=2011. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.|pdf=|usr=}}
| |
| − | {{tp|p=12101132|t=2002. The role of magnesium in the emergency department.|pdf=|usr=}}
| |
| − | {{tp|p=31911979|t=2019. Loperamide overdose causing torsades de pointes and requiring Impella temporary mechanical support: a case report.|pdf=|usr=}}
| |
| − | {{tp|p=24940425|t=2014. Increasing gap junction coupling suppresses ibutilide-induced torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=29731714|t=2018. Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes.|pdf=|usr=}}
| |
| − | {{tp|p=30270992|t=2018. Effect of Hemodialysis on Corrected QT Interval and QTc Dispersion.|pdf=|usr=}}
| |
| − | {{tp|p=22529489|t=2012. Phenytoin in treatment of amiodarone-induced Torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=19646241|t=2009. Prolonged QT interval in a man with anorexia nervosa.|pdf=|usr=}}
| |
| − | {{tp|p=30305584|t=2018. Persistent QT Prolongation in a Child with Gitelman Syndrome and SCN5A H558R Polymorphism.|pdf=|usr=}}
| |
| − | {{tp|p=20720356|t=2010. Premature atrial contraction induces torsades de pointes in a patient of Takotsubo cardiomyopathy with QT prolongation.|pdf=|usr=}}
| |
| − | {{tp|p=9372331|t=1997. Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia.|pdf=|usr=}}
| |
| − | {{tp|p=19377216|t=2008. Improvement of maximum corrected QT and corrected QT dispersion in electrocardiography after kidney transplantation.|pdf=|usr=}}
| |
| − | {{tp|p=28471572|t=2016. Magnesium-Responsive Polymorphic Ventricular Tachycardia Associated with Alcoholic Binge Drinking.|pdf=|usr=}}
| |
| − | {{tp|p=31221261|t=2019. Effects of Calcium, Magnesium, and Potassium Concentrations on Ventricular Repolarization in Unselected Individuals.|pdf=|usr=}}
| |
| − | {{tp|p=11583899|t=2001. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=2661626|t=1989. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations?|pdf=|usr=}}
| |
| − | {{tp|p=3711493|t=1986. Effects of magnesium sulfate on cardiac conduction and refractoriness in humans.|pdf=|usr=}}
| |
| − | {{tp|p=6630761|t=1983. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients.|pdf=|usr=}}
| |
| − | {{tp|p=26802105|t=2016. Serum Magnesium and the Risk of Death From Coronary Heart Disease and Sudden Cardiac Death.|pdf=|usr=}}
| |
| − | {{tp|p=10361868|t=1999. QT dispersion in patients with end-stage renal failure and during hemodialysis.|pdf=|usr=}}
| |
| − | {{tp|p=10405219|t=1999. Hypomagnesemia.|pdf=|usr=}}
| |
| − | {{tp|p=29021858|t=2017. Landiolol suppression of electrical storm of torsades de pointes in patients with congenital long-QT syndrome type 2 and myocardial ischemia.|pdf=|usr=}}
| |
| − | {{tp|p=19944332|t=2009. Torsades de Pointes with QT prolongation related to donepezil use.|pdf=|usr=}}
| |
| − | {{tp|p=24653589|t=2013. Torsade de pointes as a reperfusion arrhythmia following intravenous thrombolytic therapy.|pdf=|usr=}}
| |
| − | {{tp|p=22394705|t=2012. Pseudohypoparathyroidism presenting with ventricular arrhythmia: a case report.|pdf=|usr=}}
| |
| − | {{tp|p=16533896|t=2006. Functional roles of charged amino acid residues on the wall of the cytoplasmic pore of Kir2.1.|pdf=|usr=}}
| |
| − | {{tp|p=12407079|t=2002. Ser165 in the second transmembrane region of the Kir2.1 channel determines its susceptibility to blockade by intracellular Mg2+.|pdf=|usr=}}
| |
| − | {{tp|p=9382895|t=1997. A conserved arginine residue in the pore region of an inward rectifier K channel (IRK1) as an external barrier for cationic blockers.|pdf=|usr=}}
| |
| − | {{tp|p=8740374|t=1996. Fast inactivation causes rectification of the IKr channel.|pdf=|usr=}}
| |
| − | {{tp|p=10205594|t=1999. Life-threatening ventricular tachycardia due to liquorice-induced hypokalaemia.|pdf=|usr=}}
| |
| − | {{tp|p=11410700|t=2001. A case of torsade de pointes associated with hypopituitarism due to hemorrhagic fever with renal syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=18821491|t=2008. Cardiotoxicity after massive amantadine overdose.|pdf=|usr=}}
| |
| − | {{tp|p=18570170|t=2008. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest.|pdf=|usr=}}
| |
| − | {{tp|p=20015154|t=2010. Cholesterol modulates ion channels via down-regulation of phosphatidylinositol 4,5-bisphosphate.|pdf=|usr=}}
| |
| − | {{tp|p=15618275|t=2005. Two Kir2.1 channel populations with different sensitivities to Mg(2+) and polyamine block: a model for the cardiac strong inward rectifier K(+) channel.|pdf=|usr=}}
| |
| − | {{tp|p=12205194|t=2002. Cytosolic Ca2+ triggers early afterdepolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=12411513|t=2002. Identification of a site involved in the block by extracellular Mg(2+) and Ba(2+) as well as permeation of K(+) in the Kir2.1 K(+) channel.|pdf=|usr=}}
| |
| − | {{tp|p=10066894|t=1999. Kir2.1 encodes the inward rectifier potassium channel in rat arterial smooth muscle cells.|pdf=|usr=}}
| |
| − | {{tp|p=9508824|t=1998. Voltage-dependent blockade of HERG channels expressed in Xenopus oocytes by external Ca2+ and Mg2+.|pdf=|usr=}}
| |
| − | {{tp|p=7884731|t=1994. Torsades de pointes-like polymorphic ventricular tachycardia in a dog.|pdf=|usr=}}
| |
| − | {{tp|p=29759319|t=2015. Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures.|pdf=|usr=}}
| |
| − | {{tp|p=10875735|t=2000. Effect of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential.|pdf=|usr=}}
| |
| − | {{tp|p=12110021|t=2002. Electrocardiogram with prolonged QT interval in Gitelman disease.|pdf=|usr=}}
| |
| − | {{tp|p=30596175|t=2019. Clinical and Genetic Characteristics in Patients With Gitelman Syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=23755081|t=2013. Acquired Long QT Syndrome Manifesting with Torsades de Pointes in a Patient with Panhypopituitarism due to Radiotherapy.|pdf=|usr=}}
| |
| − | {{tp|p=25558343|t=2014. Ventricular arrhythmia in patients with prolonged QT interval during liver transplantation: two cases report.|pdf=|usr=}}
| |
| − | {{tp|p=24578711|t=2014. Channelopathies.|pdf=|usr=}}
| |
| − | {{tp|p=21977140|t=2010. Polymorphic ventricular tachycardia in acute myocardial infarction treated by thrombolysis: reperfusion, complication or iatrogenic sign?|pdf=|usr=}}
| |
| − | {{tp|p=25967879|t=2015. The relationship between repolarization parameters and serum electrolyte levels in patients with J wave syndromes.|pdf=|usr=}}
| |
| − | {{tp|p=26878253|t=2015. An approach to the diagnosis and management of a case presenting with recurrent hypomagnesemia secondary to the chronic use of a proton pump inhibitor.|pdf=|usr=}}
| |
| − | {{tp|p=20353903|t=2010. Magnesium and cardiovascular system.|pdf=|usr=}}
| |
| − | {{tp|p=30558036|t=2018. Aldosteronism with mild hypokalemia presenting as life-threatening ventricular arrhythmias: A case report.|pdf=|usr=}}
| |
| − | {{tp|p=29245320|t=2017. QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature.|pdf=|usr=}}
| |
| − | {{tp|p=30169383|t=2019. Critical Consideration of Myxedema Coma in the Postoperative Setting: A Case Report.|pdf=|usr=}}
| |
| − | {{tp|p=25470888|t=2014. A comparison of the effects of lidocaine or magnesium sulfate on hemodynamic response and QT dispersion related with intubation in patients with hypertension.|pdf=|usr=}}
| |
| − | {{tp|p=24397608|t=2014. Drug-induced long QT syndrome and fatal arrhythmias in the intensive care unit.|pdf=|usr=}}
| |
| − | {{tp|p=11942876|t=2002. Perioperative management of long QT syndrome in a child with congenital heart disease.|pdf=|usr=}}
| |
| − | {{tp|p=20128168|t=2009. Gastroenteritis with severe consequences: a case of sotalol-induced torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=30220246|t=2019. Hypomagnesemia and hypermagnesemia.|pdf=|usr=}}
| |
| − | {{tp|p=24697004|t=2013. A case of recurrent arrhythmia in an acute pancreatitis patient--pathophysiological explanation using shortage of 'repolarization reserve'.|pdf=|usr=}}
| |
| − | {{tp|p=3993440|t=1985. The relationship between QTc changes and nutrition during weight loss after gastroplasty.|pdf=|usr=}}
| |
| − | {{tp|p=10830458|t=2000. Heart risk associated with weight loss in anorexia nervosa and eating disorders: electrocardiographic changes during the early phase of refeeding.|pdf=|usr=}}
| |
| − | {{tp|p=16156840|t=2005. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine.|pdf=|usr=}}
| |
| − | {{tp|p=12534434|t=2003. The importance of the QT interval: a review of the literature.|pdf=|usr=}}
| |
| − | {{tp|p=7572567|t=1995. Torsades de pointes and long QT syndromes.|pdf=|usr=}}
| |
| − | {{tp|p=17540188|t=2007. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=14597941|t=2003. Evaluation of the dofetilide risk-management program.|pdf=|usr=}}
| |
| − | {{tp|p=11773906|t=2002. Long QT syndrome: diagnosis and management.|pdf=|usr=}}
| |
| − | {{tp|p=2729056|t=1989. Effect of the infusion of magnesium sulfate during atrial pacing on ECG intervals, serum electrolytes, and blood pressure.|pdf=|usr=}}
| |
| − | {{tp|p=49775|t=1975. Letter: Glycerol in cerebral oedema.|pdf=|usr=}}
| |
| − | {{tp|p=31942276|t=2020. Mirtazapine's effect on the QT interval in medically hospitalized patients.|pdf=|usr=}}
| |
| − | {{tp|p=22470374|t=2011. QT Interval and QT Dispersion in Patients Undergoing Hemodialysis: Revisiting the Old Theory.|pdf=|usr=}}
| |
| − | {{tp|p=27471598|t=2016. Hypomagnesemia as a potentially life-threatening adverse effect of omeprazole.|pdf=|usr=}}
| |
| − | {{tp|p=24155819|t=2012. Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation.|pdf=|usr=}}
| |
| − | {{tp|p=25350118|t=2014. Lack of negatively charged residues at the external mouth of Kir2.2 channels enable the voltage-dependent block by external Mg2+.|pdf=|usr=}}
| |
| − | {{tp|p=24681627|t=2014. A long QT mutation substitutes cholesterol for phosphatidylinositol-4,5-bisphosphate in KCNQ1 channel regulation.|pdf=|usr=}}
| |
| − | {{tp|p=12151568|t=2002. Changes in the corrected QT interval and corrected QT dispersion during haemodialysis.|pdf=|usr=}}
| |
| − | {{tp|p=1409197|t=1992. Sotalol-induced torsade de pointes: management with magnesium infusion.|pdf=|usr=}}
| |
| − | {{tp|p=3341171|t=1988. Electrophysiologic effects of intravenous magnesium in patients with normal conduction systems and no clinical evidence of significant cardiac disease.|pdf=|usr=}}
| |
| − | {{tp|p=3766386|t=1986. Efficacy of magnesium sulfate in the treatment of torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=3966318|t=1985. Torsade de pointes and magnesium deficiency.|pdf=|usr=}}
| |
| − | {{tp|p=20723644|t=2010. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent.|pdf=|usr=}}
| |
| − | {{tp|p=12767447|t=2003. Prenatal diagnosis and in utero treatment of torsades de pointes associated with congenital long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=12586278|t=2003. Effect of short- and long-duration spaceflight on QTc intervals in healthy astronauts.|pdf=|usr=}}
| |
| − | {{tp|p=9354415|t=1997. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.|pdf=|usr=}}
| |
| − | {{tp|p=2296905|t=1990. Magnesium sulfate is the treatment for torsades de pointes if the right dose is given.|pdf=|usr=}}
| |
| − | {{tp|p=2729150|t=1989. Treatment of torsade de pointes with intravenous magnesium.|pdf=|usr=}}
| |
| − | {{tp|p=2650516|t=1989. Magnesium treatment of ventricular arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=6695782|t=1984. Magnesium therapy for torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=6650429|t=1983. Hypomagnesemic torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=14728075|t=2003. Does magnesium have a role in the treatment of patients with coronary artery disease?|pdf=|usr=}}
| |
| − | {{tp|p=8358483|t=1993. The importance of magnesium in cardiovascular disease.|pdf=|usr=}}
| |
| − | {{tp|p=27914889|t=2017. Ventricular tachycardia and prolonged QT interval presenting as seizure-like activity.|pdf=|usr=}}
| |
| − | {{tp|p=24462399|t=2014. The use of isoproterenol and phenytoin to reverse torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=23896010|t=2013. Citalopram and levosulpiride: a dangerous drug combination for QT prolongation.|pdf=|usr=}}
| |
| − | {{tp|p=21075581|t=2012. Isoproterenol as an adjunct for treatment of idiopathic ventricular fibrillation storm in a pregnant woman.|pdf=|usr=}}
| |
| − | {{tp|p=20006210|t=2010. Termination of drug-induced torsades de pointes with overdrive pacing.|pdf=|usr=}}
| |
| − | {{tp|p=19857426|t=2009. Long QT syndrome and torsades de pointes induced by acute sulpiride poisoning.|pdf=|usr=}}
| |
| − | {{tp|p=9928709|t=1999. Torsades de pointes: a case with multiple variables.|pdf=|usr=}}
| |
| − | {{tp|p=7945604|t=1994. Torsades de pointes induced by erythromycin and terfenadine.|pdf=|usr=}}
| |
| − | {{tp|p=2914039|t=1989. Magnesium sulfate termination of torsades de pointes following failure of cardioversion.|pdf=|usr=}}
| |
| − | {{tp|p=7733096|t=1995. Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance.|pdf=|usr=}}
| |
| − | {{tp|p=18359968|t=2008. Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis.|pdf=|usr=}}
| |
| − | {{tp|p=15119574|t=2004. Model of effect of magnesium prophylaxis on frequency of torsades de pointes in ibutilide-treated patients.|pdf=|usr=}}
| |
| − | {{tp|p=8438899|t=1993. Induction of hypomagnesemia during Amsacrine treatment.|pdf=|usr=}}
| |
| − | {{tp|p=25864370|t=2015. Magnesium and Dialysis: The Neglected Cation.|pdf=|usr=}}
| |
| − | {{tp|p=25828570|t=2015. Dialysate and serum potassium in hemodialysis.|pdf=|usr=}}
| |
| − | {{tp|p=12500237|t=2003. Cell-associated magnesium and QT dispersion in hemodialysis patients.|pdf=|usr=}}
| |
| − | {{tp|p=27639872|t=2017. Association of Serum Magnesium on Mortality in Patients Admitted to the Intensive Cardiac Care Unit.|pdf=|usr=}}
| |
| − | {{tp|p=11812408|t=2002. Clinical and therapeutic aspects of congenital and acquired long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=3499072|t=1987. Torsade de pointes during administration of pentamidine isethionate.|pdf=|usr=}}
| |
| − | {{tp|p=3565423|t=1987. Effects of low potassium or magnesium concentrations on isolated cardiac tissue.|pdf=|usr=}}
| |
| − | {{tp|p=20610973|t=2010. A dyshomeostasis of electrolytes and trace elements in acute stressor states: impact on the heart.|pdf=|usr=}}
| |
| − | {{tp|p=7771501|t=1995. Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication.|pdf=|usr=}}
| |
| − | {{tp|p=8475949|t=1993. Case report: pentamidine and polymorphic ventricular tachycardia revisited.|pdf=|usr=}}
| |
| − | {{tp|p=12832258|t=2003. Side effects of ziprasidone.|pdf=|usr=}}
| |
| − | {{tp|p=14704599|t=2004. Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis.|pdf=|usr=}}
| |
| − | {{tp|p=12845389|t=2003. Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter: impact of race on efficacy and safety.|pdf=|usr=}}
| |
| − | {{tp|p=11304665|t=2001. Influence of electrolyte abnormalities on interlead variability of ventricular repolarization times in 12-lead electrocardiography.|pdf=|usr=}}
| |
| − | {{tp|p=11197564|t=2001. Prevalence and prognostic importance of hypomagnesemia and hypocalcemia in horses that have colic surgery.|pdf=|usr=}}
| |
| − | {{tp|p=21364460|t=2011. Magnesium--essentials for anesthesiologists.|pdf=|usr=}}
| |
| − | {{tp|p=2301766|t=1990. The effect of magnesium sulfate administration on cerebral and cardiac toxicity of bupivacaine in dogs.|pdf=|usr=}}
| |
| − | {{tp|p=12678199|t=2003. Amiodarone-induced torsade de pointes during bladder irrigation: an unusual presentation--a case report.|pdf=|usr=}}
| |
| − | {{tp|p=10870859|t=2000. Increased QT interval dispersion after hemodialysis: role of peridialytic electrolyte gradients.|pdf=|usr=}}
| |
| − | {{tp|p=2389840|t=1990. Magnesium treatment of torsade de pointes--a case report.|pdf=|usr=}}
| |
| − | {{tp|p=2629617|t=1989. Proprietes electrophysiologiques cliniques du magnesium et correlations avec son efficacite anti-arythmique dans les torsades de pointe acquises.|pdf=|usr=}}
| |
| − | {{tp|p=8599503|t=1996. Magnesium sulfate for conversion of supraventricular tachycardia refractory to intravenous adenosine.|pdf=|usr=}}
| |
| − | {{tp|p=2817575|t=1989. Magnesium sulfate & torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=3304038|t=1987. Torsades de pointes: atypical rhythm, atypical treatment.|pdf=|usr=}}
| |
| − | {{tp|p=8572407|t=1995. Indications du magnesium en anesthesie-reanimation.|pdf=|usr=}}
| |
| − | {{tp|p=1363741|t=1992. Effets arythmogenes du chlorydrate de sultopride: correlation clinique et electrophysiologique cellulaire.|pdf=|usr=}}
| |
| − | {{tp|p=2418718|t=1985. Torsades de pointe et hypomagnesemie.|pdf=|usr=}}
| |
| − | {{tp|p=7469224|t=1981. Torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=3152846|t=1988. Il solfato di magnesio nella terapia della tachicardia ventricolare a torsione di punta.|pdf=|usr=}}
| |
| − | {{tp|p=24285766|t=2013. Azithromycin-induced proarrhythmia and cardiovascular death.|pdf=|usr=}}
| |
| − | {{tp|p=23362038|t=2013. Torsades de pointes after administration of low-dose aripiprazole.|pdf=|usr=}}
| |
| − | {{tp|p=10534216|t=1999. Haloperidol-induced torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=1477438|t=1992. Prolonged recurrence of pentamidine-induced torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=7786143|t=1995. Mecanisme d'action des antiarythmiques de classe III.|pdf=|usr=}}
| |
| − | {{tp|p=8267505|t=1993. Les torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=1550438|t=1992. Effets du magnesium sur les post-depolarisations precoces et l'activite declenchee induites par le cesium sur les fibres de Purkinje de furet.|pdf=|usr=}}
| |
| − | {{tp|p=3122681|t=1987. Effets electrophysiologiques du sulfate de magnesium intraveineux chez l'homme.|pdf=|usr=}}
| |
| − | {{tp|p=3087320|t=1986. Effets anti-arythmiques du sulfate de magnesium intraveineux dans les torsades de pointes. A propos de 6 observations.|pdf=|usr=}}
| |
| − | {{tp|p=3096233|t=1986. Traitement des torsades de pointes par magnesium intraveineux.|pdf=|usr=}}
| |
| − | {{tp|p=28766238|t=2017. Magnesium isoglycyrrhizinate inhibits L-type Ca(2+) channels, Ca(2+) transients, and contractility but not hERG K(+) channels.|pdf=|usr=}}
| |
| − | {{tp|p=14692159|t=2003. Torsades de pointes following cardioversion: case history and literature review.|pdf=|usr=}}
| |
| − | {{tp|p=2196873|t=1990. Proarrhythmic actions of antiarrhythmic drugs: a review.|pdf=|usr=}}
| |
| − | {{tp|p=9782371|t=1998. Generating and influencing Torsades de Pointes--like polymorphic ventricular tachycardia in isolated guinea pig hearts.|pdf=|usr=}}
| |
| − | {{tp|p=19653656|t=2009. Ion-blocking sites of the Kir2.1 channel revealed by multiscale modeling.|pdf=|usr=}}
| |
| − | {{tp|p=22057978|t=2012. Inhibition of sodium current by taurine magnesium coordination compound prevents cesium chloride-induced arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=19655100|t=2010. Clinical effects of cesium intake.|pdf=|usr=}}
| |
| − | {{tp|p=10958097|t=2000. Management of prolonged QT interval during a massive transfusion: calcium, magnesium or both?|pdf=|usr=}}
| |
| − | {{tp|p=8595691|t=1995. Diuretic-induced hypokalaemia inducing torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=9627533|t=1998. Torsade de pointes with sotalol overdose treated successfully with lidocaine.|pdf=|usr=}}
| |
| − | {{tp|p=19935903|t=2009. Inhibitory effects of dauricine on early afterdepolarizations and L-type calcium current.|pdf=|usr=}}
| |
| − | {{tp|p=11007539|t=2000. Block of inwardly rectifying K+ currents by extracellular Mg2+ and Ba2+ in bovine pulmonary artery endothelial cells.|pdf=|usr=}}
| |
| − | {{tp|p=20544619|t=2010. Multifactorial QT interval prolongation.|pdf=|usr=}}
| |
| − | {{tp|p=14766022|t=2004. Vitamins, supplements, herbal medicines, and arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=10348955|t=1998. Acquired QT Prolongation: Mechanisms and Implications.|pdf=|usr=}}
| |
| − | {{tp|p=2085823|t=1990. Magnesium and cardiac arrhythmias. Reappraisal of an old substance.|pdf=|usr=}}
| |
| − | {{tp|p=12652102|t=2002. The influence of magnesium on the electrophysiological effects of erythromycin in the isolated Guinea pig heart.|pdf=|usr=}}
| |
| − | {{tp|p=1854660|t=1991. Torsades de pointes: prevention and therapy.|pdf=|usr=}}
| |
| − | {{tp|p=1854659|t=1991. Terminology of torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=9231028|t=1997. Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium.|pdf=|usr=}}
| |
| − | {{tp|p=9302346|t=1997. Magnesium abolishes inadequate kinetics of frequency adaptation of the Q-aT interval in the presence of sotalol.|pdf=|usr=}}
| |
| − | {{tp|p=8001044|t=1994. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts.|pdf=|usr=}}
| |
| − | {{tp|p=3256422|t=1988. Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms.|pdf=|usr=}}
| |
| − | {{tp|p=29873021|t=2018. The Effects of Lipid Emulsion, Magnesium Sulphate and Metoprolol in Amitriptyline-Induced Cardiovascular Toxicity in Rats.|pdf=|usr=}}
| |
| − | {{tp|p=25253561|t=2015. Analysis of an ECG record database reveals QT interval prolongation potential of famotidine in a large Korean population.|pdf=|usr=}}
| |
| − | {{tp|p=18690034|t=2007. Exaggerated Mg2+ inhibition of Kir2.1 as a consequence of reduced PIP2 sensitivity in Andersen syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=19433077|t=2009. Modulation of haloperidol induced electrophysiological alterations on cardiac action potential by various risk factors and gender difference.|pdf=|usr=}}
| |
| − | {{tp|p=8131528|t=1994. Magnesium sulfate potentiates several cardiovascular and metabolic actions of terbutaline.|pdf=|usr=}}
| |
| − | {{tp|p=15746441|t=2005. Impaired KCNQ1-KCNE1 and phosphatidylinositol-4,5-bisphosphate interaction underlies the long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=9598592|t=1998. Dynamic Ca2+-induced inward rectification of K+ current during the ventricular action potential.|pdf=|usr=}}
| |
| − | {{tp|p=9168780|t=1997. Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells.|pdf=|usr=}}
| |
| − | {{tp|p=7828315|t=1995. Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block.|pdf=|usr=}}
| |
| − | {{tp|p=1914096|t=1991. Polymorphous ventricular tachycardia associated with acute myocardial infarction.|pdf=|usr=}}
| |
| − | {{tp|p=2917391|t=1989. Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers. Effects of stimulation rate, potassium, and magnesium.|pdf=|usr=}}
| |
| − | {{tp|p=3370776|t=1988. Magnesium suppression of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium in dogs.|pdf=|usr=}}
| |
| − | {{tp|p=3338130|t=1988. Treatment of torsade de pointes with magnesium sulfate.|pdf=|usr=}}
| |
| − | {{tp|p=22846359|t=2012. [Magnesium metabolism and therapeutic strategy in cardiovascular disease].|pdf=|usr=}}
| |
| − | {{tp|p=15692161|t=2005. [Heart rate variability, arrhythmia and magnesium in hemodialysis patients].|pdf=|usr=}}
| |
| − | {{tp|p=11453949|t=2001. Hyperthyroidism is associated with lengthening of ventricular repolarization.|pdf=|usr=}}
| |
| − | {{tp|p=16698131|t=2006. Tolerable infusion rate of citrate based on clinical signs and the electrocardiogram in conscious dogs.|pdf=|usr=}}
| |
| − | {{tp|p=2416504|t=1985. Drug-induced torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=15001976|t=2004. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.|pdf=|usr=}}
| |
| − | {{tp|p=2974361|t=1988. Il problema della tachicardia ventricolare a torsione di punta e della sua razionale terapia.|pdf=|usr=}}
| |
| − | {{tp|p=27022002|t=2016. Not your regular high: cardiac dysrhythmias caused by loperamide.|pdf=|usr=}}
| |
| − | {{tp|p=20671821|t=2010. Causes and management of drug-induced long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=22299661|t=2012. The effect of different dialysate magnesium concentrations on QTc dispersion in hemodialysis patients.|pdf=|usr=}}
| |
| − | {{tp|p=26869275|t=2016. A synergistic blocking effect of Mg(2)(+) and spermine on the inward rectifier K(+) (Kir2.1) channel pore.|pdf=|usr=}}
| |
| − | {{tp|p=25630313|t=2014. Importance of QT interval in clinical practice.|pdf=|usr=}}
| |
| − | {{tp|p=31637554|t=2019. Temporary loss of consciousness during cetuximab treatment of a patient with metastatic colon cancer: a case report.|pdf=|usr=}}
| |
| − | {{tp|p=15616901|t=2004. Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy.|pdf=|usr=}}
| |
| − | {{tp|p=32603470|t=2020. Acquired Long QT Syndrome after Acute Myocardial Infarction: A Rare but Potentially Fatal Entity.|pdf=|usr=}}
| |
| − | {{tp|p=25057346|t=2014. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports.|pdf=|usr=}}
| |
| − | {{tp|p=19907690|t=2009. Drugs, electrolytes and tako-tsubo cardiomyopathy: triple aetiology of acquired long QT syndrome and torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=25706450|t=2015. Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.|pdf=|usr=}}
| |
| − | {{tp|p=20199131|t=2010. A case of torsades de pointes induced by severe QT prolongation after an overdose of eperisone and triazolam in a patient receiving nifedipine.|pdf=|usr=}}
| |
| − | {{tp|p=18363122|t=2008. Non-fatal ventricular dysrhythmias associated with severe salicylate toxicity.|pdf=|usr=}}
| |
| − | {{tp|p=22668123|t=2012. Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management.|pdf=|usr=}}
| |
| − | {{tp|p=21649448|t=2011. Assessing QT interval prolongation and its associated risks with antipsychotics.|pdf=|usr=}}
| |
| − | {{tp|p=2129926|t=1990. Torsades de Pointes.|pdf=|usr=}}
| |
| − | {{tp|p=17879860|t=2007. Prolonged QTc intervals on admission electrocardiograms: prevalence and correspondence with admission electrolyte abnormalities.|pdf=|usr=}}
| |
| − | {{tp|p=1989768|t=1991. Cardiac arrest secondary to emotional stress and torsade de pointes in a patient with associated magnesium and potassium deficiency.|pdf=|usr=}}
| |
| − | {{tp|p=3257726|t=1988. Torsade de pointes in a patient receiving intravenous vasopressin.|pdf=|usr=}}
| |
| − | {{tp|p=19281438|t=2009. The relationship between blood glucose level and QTc duration in the critically ill.|pdf=|usr=}}
| |
| − | {{tp|p=16573402|t=2002. Cardiac arrhythmias: diagnosis and management. The tachycardias.|pdf=|usr=}}
| |
| − | {{tp|p=12917054|t=2003. Advances in the acute pharmacologic management of cardiac arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=24020938|t=2013. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.|pdf=|usr=}}
| |
| − | {{tp|p=11096483|t=1999. Torsades de Pointes.|pdf=|usr=}}
| |
| − | {{tp|p=26249264|t=2015. QT interval prolongation associated with low magnesium in chronic alcoholics.|pdf=|usr=}}
| |
| − | {{tp|p=27241860|t=2017. The prevalence of QT prolongation in a population of patients with substance use disorders.|pdf=|usr=}}
| |
| − | {{tp|p=22702639|t=2012. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.|pdf=|usr=}}
| |
| − | {{tp|p=11994029|t=2002. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.|pdf=|usr=}}
| |
| − | {{tp|p=7727055|t=1994. Drug-induced torsade de pointes. Incidence, management and prevention.|pdf=|usr=}}
| |
| − | {{tp|p=8129865|t=1993. Class III antiarrhythmics in overdose. Presenting features and management principles.|pdf=|usr=}}
| |
| − | {{tp|p=10553703|t=1999. Toxicity of quinolones.|pdf=|usr=}}
| |
| − | {{tp|p=7510621|t=1994. Torsade de pointes. Mechanisms and management.|pdf=|usr=}}
| |
| − | {{tp|p=20210367|t=2010. Safety considerations of fluoroquinolones in the elderly: an update.|pdf=|usr=}}
| |
| − | {{tp|p=12641485|t=2003. Fluoroquinolones in the elderly: safety considerations.|pdf=|usr=}}
| |
| − | {{tp|p=11740632|t=2001. QT-Verlangerung und Torsade de pointes-Tachykardie bei Therapie mit Maprotilin. Differenzialdiagnostische und -therapeutische Aspekte.|pdf=|usr=}}
| |
| − | {{tp|p=7588195|t=1995. Wide complex tachycardia.|pdf=|usr=}}
| |
| − | {{tp|p=11217540|t=2000. Antipsychotiques et securite cardio-vasculaire: donnees actuelles sur les allongements de l'intervalle QT et le risque d'arythmies ventriculaires.|pdf=|usr=}}
| |
| − | {{tp|p=10099907|t=1999. Decreases by magnesium of QT dispersion and ventricular arrhythmias in patients with acute myocardial infarction.|pdf=|usr=}}
| |
| − | {{tp|p=8293755|t=1993. Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization.|pdf=|usr=}}
| |
| − | {{tp|p=27154527|t=2019. Severe Torsades de Pointes with acquired QT prolongation.|pdf=|usr=}}
| |
| − | {{tp|p=27634841|t=2017. Treating arrhythmias with adjunctive magnesium: identifying future research directions.|pdf=|usr=}}
| |
| − | {{tp|p=24817413|t=2014. Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage?|pdf=|usr=}}
| |
| − | {{tp|p=10853872|t=2000. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience.|pdf=|usr=}}
| |
| − | {{tp|p=18304526|t=2008. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct.|pdf=|usr=}}
| |
| − | {{tp|p=22389418|t=2012. In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights.|pdf=|usr=}}
| |
| − | {{tp|p=19351630|t=2009. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation.|pdf=|usr=}}
| |
| − | {{tp|p=10362846|t=1999. Effect of extracellular cations on the inward rectifying K+ channels Kir2.1 and Kir3.1/Kir3.4.|pdf=|usr=}}
| |
| − | {{tp|p=23808631|t=2013. Hypomagnesemia and proton-pump inhibitors.|pdf=|usr=}}
| |
| − | {{tp|p=14585064|t=2003. Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use.|pdf=|usr=}}
| |
| − | {{tp|p=31092056|t=2019. Proton pump inhibitor-induced hypomagnesemia complicated with serious cardiac arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=24147515|t=2013. Torsades de pointes following clarithromycin treatment.|pdf=|usr=}}
| |
| − | {{tp|p=14977544|t=2004. Magnesium in clinical medicine.|pdf=|usr=}}
| |
| − | {{tp|p=8458600|t=1993. Experimental models of torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=3436500|t=1987. I sali di magnesio nel trattamento della tachicardia ventricolare.|pdf=|usr=}}
| |
| − | {{tp|p=3556945|t=1986. Un caso di torsione di punta da ipomagnesiemia.|pdf=|usr=}}
| |
| − | {{tp|p=3556944|t=1986. "Torsione di punta" da antidepressivi triciclici. Descrizione di un caso clinico.|pdf=|usr=}}
| |
| − | {{tp|p=6532886|t=1984. Azione antiaritmica del solfato di magnesio nella aritmia ventricolare a "torsione di punta".|pdf=|usr=}}
| |
| − | {{tp|p=15750993|t=2004. Rischio aritmologico in pazienti emodializzati vs soggetti normali.|pdf=|usr=}}
| |
| − | {{tp|p=22847284|t=2012. Electrocardiographic, cardiac enzymes, and magnesium in patients with severe acute pancreatitis.|pdf=|usr=}}
| |
| − | {{tp|p=9888262|t=1999. Antiarrhythmic effects of magnesium on rat papillary muscle and guinea pig ventricular myocytes.|pdf=|usr=}}
| |
| − | {{tp|p=10461849|t=1999. Effects of nicardipine and bupivacaine on early after depolarization in rabbit sinoatrial node cells: a possible mechanism of bupivacaine-induced arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=21411146|t=2011. Methadone-induced torsades de pointes: a twist of fate.|pdf=|usr=}}
| |
| − | {{tp|p=9333595|t=1997. Medikamentose antiarrhythmische Therapie. Ist eine orale adjuvante Therapie mit Elektrolyten sinnvoll?|pdf=|usr=}}
| |
| − | {{tp|p=9333593|t=1997. Magnesiummangel und Magnesiumsubstitution. Einfluss auf ventrikulare Herzrhythmusstorungen unterschiedlicher Atiologie.|pdf=|usr=}}
| |
| − | {{tp|p=9333592|t=1997. Einfluss von Magnesium auf anhaltende ventrikulare Tachykardien.|pdf=|usr=}}
| |
| − | {{tp|p=9333591|t=1997. Klinisch-elektrophysiologische Effekte von Magnesium, insbesondere bei supraventrikularen Tachykardien.|pdf=|usr=}}
| |
| − | {{tp|p=32025785|t=2020. Long- und Short-QT-Syndrome : Notfalltherapie und Sekundarprophylaxe.|pdf=|usr=}}
| |
| − | {{tp|p=9821023|t=1998. Q-T interval prolongation and pleomorphic ventricular tachyarrhythmia ('Torsade de pointes') in organophosphate poisoning: report of a case.|pdf=|usr=}}
| |
| − | {{tp|p=15586745|t=2004. Seventy-four defibrillations for sotalol-induced torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=3229780|t=1988. Magnesium sulfate therapy in torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=16096514|t=2005. Antipsychotic drugs and QT prolongation.|pdf=|usr=}}
| |
| − | {{tp|p=28100427|t=2017. The possible role of propofol in drug-induced torsades de pointes: A real-world single-center analysis.|pdf=|usr=}}
| |
| − | {{tp|p=19136164|t=2010. Pre-injection of magnesium sulfate enhances the efficacy of ibutilide for the conversion of typical but not of atypical persistent atrial flutter.|pdf=|usr=}}
| |
| − | {{tp|p=15301901|t=2004. Magnesium in treatment of acute myocardial infarction.|pdf=|usr=}}
| |
| − | {{tp|p=15159030|t=2004. Novel therapeutics for treatment of long-QT syndrome and torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=15193823|t=2004. Female preponderance in ibutilide-induced torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=11203051|t=2000. Torsades de pointes due to multihormonal deficiency induced long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=2365519|t=1990. Magnesium sulphate for torsade de pointes in a patient with congenital long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=3744606|t=1986. Limited effect of magnesium sulphate on torsades de pointes ventricular tachycardia.|pdf=|usr=}}
| |
| − | {{tp|p=28012118|t=2017. Risk factors for QTc-prolongation: systematic review of the evidence.|pdf=|usr=}}
| |
| − | {{tp|p=9744153|t=1998. Hypomagnesaemia in postoperative patients: an important contributing factor in postoperative mortality.|pdf=|usr=}}
| |
| − | {{tp|p=21496406|t=2011. The use of first generation versus second generation antipsychotics as add-on or as switch treatment and its effect on QTC interval: the Italian experience in a real-world setting.|pdf=|usr=}}
| |
| − | {{tp|p=27943168|t=2017. Hemodialysis-induced repolarization abnormalities on ECG are influenced by serum calcium levels and ultrafiltration volumes.|pdf=|usr=}}
| |
| − | {{tp|p=12122531|t=2002. Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed.|pdf=|usr=}}
| |
| − | {{tp|p=14689085|t=2003. Tetanie.|pdf=|usr=}}
| |
| − | {{tp|p=11305536|t=2001. Amiodarone-induced torsade de pointes in a child with dilated cardiomyopathy.|pdf=|usr=}}
| |
| − | {{tp|p=11760927|t=2001. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).|pdf=|usr=}}
| |
| − | {{tp|p=17212573|t=2006. Acquired long QT syndrome secondary to cesium chloride supplement.|pdf=|usr=}}
| |
| − | {{tp|p=15466950|t=2004. Optimal administration dosage of magnesium sulfate for torsades de pointes in children with long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=3537078|t=1986. Magnesium and cardiac arrhythmias: nutrient or drug?|pdf=|usr=}}
| |
| − | {{tp|p=15278621|t=1991. Effects of lidocaine and verapamil on early afterdepolarizations in isolated rabbit sinoatrial node.|pdf=|usr=}}
| |
| − | {{tp|p=15270138|t=2004. Drug-induced long QT syndrome and Torsade de Pointes.|pdf=|usr=}}
| |
| − | {{tp|p=10999172|t=1999. Hypomagnesemia with hypokalemia in an uncontrolled diabetic patient presenting with recurrent episodes of torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=17987843|t=2007. [Despite medication, overdrive pacing is required to stabilize the electrical storm associated with acute coronary syndrome: a case report].|pdf=|usr=}}
| |
| − | {{tp|p=9253694|t=1997. [Pheochromocytoma of the left retroperitoneal paraganglion associated with torsade de pointes: a case report].|pdf=|usr=}}
| |
| − | {{tp|p=26706796|t=2015. Sudden Cardiac Death and Disorders of the QT Interval: Anesthetic Implications and Focus on Perioperative Management.|pdf=|usr=}}
| |
| − | {{tp|p=12108503|t=2002. Beta-adrenergic stimulation of pig myocytes with decreased cytosolic free magnesium prolongs the action potential and enhances triggered activity.|pdf=|usr=}}
| |
| − | {{tp|p=10355707|t=1999. Macroscopic T wave alternans as a harbinger of sudden death.|pdf=|usr=}}
| |
| − | {{tp|p=9300294|t=1997. Tissue magnesium levels and the arrhythmic substrate in humans.|pdf=|usr=}}
| |
| − | {{tp|p=9363818|t=1997. Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model.|pdf=|usr=}}
| |
| − | {{tp|p=8269292|t=1993. Drug therapy for torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=22990234|t=2013. Beat-to-beat corrected QT analysis detects corrected QT prolongation in 50 consecutive telemetry-monitored patients.|pdf=|usr=}}
| |
| − | {{tp|p=17031266|t=2006. Role of autonomic nervous activity in the antiarrhythmic effects of magnesium sulfate in a canine model of polymorphic ventricular tachyarrhythmia associated with prolonged QT interval.|pdf=|usr=}}
| |
| − | {{tp|p=10028924|t=1999. Modulation of HERG potassium channels by extracellular magnesium and quinidine.|pdf=|usr=}}
| |
| − | {{tp|p=10445681|t=1999. Female gender is a risk factor for torsades de pointes in an in vitro animal model.|pdf=|usr=}}
| |
| − | {{tp|p=9733356|t=1998. Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol, and erythromycin.|pdf=|usr=}}
| |
| − | {{tp|p=7475058|t=1995. Electrophysiological and arrhythmogenic effects of the histamine type 1-receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance.|pdf=|usr=}}
| |
| − | {{tp|p=7532749|t=1994. Effects of magnesium on polymorphic ventricular tachycardias induced by aconitine.|pdf=|usr=}}
| |
| − | {{tp|p=1697384|t=1990. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions.|pdf=|usr=}}
| |
| − | {{tp|p=1691383|t=1990. Pharmacologic response of cesium-induced ventricular tachyarrhythmias in anesthetized dogs.|pdf=|usr=}}
| |
| − | {{tp|p=10684450|t=1997. Antiarrhythmic and Arrhythmogenic Actions of Varying Levels of Extracellular Magnesium: Possible Cellular Basis for the Differences in the Efficacy of magnesium and Lidocaine in Torsade de Pointes.|pdf=|usr=}}
| |
| − | {{tp|p=24633623|t=2014. Gating of the kir2.1 channel at the bundle crossing region by intracellular spermine and other cations.|pdf=|usr=}}
| |
| − | {{tp|p=27543914|t=2017. QTc prolongation during peripheral stem cell apheresis in healthy volunteers.|pdf=|usr=}}
| |
| − | {{tp|p=31116446|t=2019. Loperamide: A Readily Available but Dangerous Opioid Substitute.|pdf=|usr=}}
| |
| − | {{tp|p=7665716|t=1995. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease.|pdf=|usr=}}
| |
| − | {{tp|p=1753009|t=1991. Electrophysiologic mechanisms for ventricular arrhythmias in left ventricular dysfunction: electrolytes, catecholamines and drugs.|pdf=|usr=}}
| |
| − | {{tp|p=12823094|t=2003. Oral magnesium ion shortens prolonged QTc interval.|pdf=|usr=}}
| |
| − | {{tp|p=27492745|t=2017. A multidisciplinary approach to prenatal treatment of congenital long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=20832817|t=2010. Torsades: adjacent and triggering electrocardiographic events.|pdf=|usr=}}
| |
| − | {{tp|p=9005884|t=1997. Torsade de pointes as a complication of subarachnoid hemorrhage: a critical reappraisal.|pdf=|usr=}}
| |
| − | {{tp|p=1735792|t=1992. Effect of strontium on action potential repolarization in rabbit sinoatrial node cells.|pdf=|usr=}}
| |
| − | {{tp|p=28755998|t=2017. Loperamide-Induced Torsades de Pointes: A Case Series.|pdf=|usr=}}
| |
| − | {{tp|p=28007361|t=2017. A Perfect Storm: Tyrosine Kinase Inhibitor-Associated Polymorphic Ventricular Tachycardia.|pdf=|usr=}}
| |
| − | {{tp|p=17976767|t=2008. Management of ventricular dysrhythmia secondary to trazodone overdose.|pdf=|usr=}}
| |
| − | {{tp|p=18022786|t=2008. Chronic methadone therapy complicated by torsades de pointes: a case report.|pdf=|usr=}}
| |
| − | {{tp|p=1491157|t=1992. Magnesium: clinical considerations.|pdf=|usr=}}
| |
| − | {{tp|p=9071844|t=1997. Combined use of astemizole and ketoconazole resulting in torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=11519837|t=2001. Alcoholic liver cirrhosis complicated with torsade de pointes during plasma exchange and hemodiafiltration.|pdf=|usr=}}
| |
| − | {{tp|p=11253252|t=2000. The electrocardiographic QT interval and its prolongation in response to medications: differences between men and women.|pdf=|usr=}}
| |
| − | {{tp|p=18846329|t=2008. Effects of potassium aspartate and magnesium on ventricular arrhythmia in ischemia-reperfusion rabbit heart.|pdf=|usr=}}
| |
| − | {{tp|p=8523384|t=1995. Two new culprits in cardiovascular disease: QT dispersion and aldosterone.|pdf=|usr=}}
| |
| − | {{tp|p=14508199|t=2003. Dynamic QT interval analysis in uraemic patients receiving chronic haemodialysis.|pdf=|usr=}}
| |
| − | {{tp|p=1316396|t=1992. Diuretic-induced potassium and magnesium deficiency: relation to drug-induced QT prolongation, cardiac arrhythmias and sudden death.|pdf=|usr=}}
| |
| − | {{tp|p=15665255|t=2005. Magnesium deficiency in critical illness.|pdf=|usr=}}
| |
| − | {{tp|p=25073261|t=2013. Treatment of methadone-induced torsades de pointes with lidocaine.|pdf=|usr=}}
| |
| − | {{tp|p=19303883|t=2009. Role of Mg(2+) block of the inward rectifier K(+) current in cardiac repolarization reserve: A quantitative simulation.|pdf=|usr=}}
| |
| − | {{tp|p=17582433|t=2007. T75M-KCNJ2 mutation causing Andersen-Tawil syndrome enhances inward rectification by changing Mg2+ sensitivity.|pdf=|usr=}}
| |
| − | {{tp|p=11829056|t=2002. Actions of Androctonus australis and Leiurus quinquestriatus venoms in the rat isolated atria and anesthetized rats; effect of magnesium and lidocaine.|pdf=|usr=}}
| |
| − | {{tp|p=19967647|t=2009. Vascular calcification and QT interval in incident hemodialysis patients.|pdf=|usr=}}
| |
| − | {{tp|p=15211156|t=2004. Traumatic subarachnoid hemorrhage and QTc prolongation.|pdf=|usr=}}
| |
| − | {{tp|p=12755529|t=2003. Woman with postpartum ventricular tachycardia and hypomagnesemia.|pdf=|usr=}}
| |
| − | {{tp|p=24353019|t=2013. Prolonged QT interval by methadone: relevance for daily practice? A prospective study in patients with cancer and noncancer pain.|pdf=|usr=}}
| |
| − | {{tp|p=12354276|t=2002. Organophosphate poisoning complicated by a tachyarrhythmia and acute respiratory distress syndrome in a child.|pdf=|usr=}}
| |
| − | {{tp|p=9580612|t=1998. Gender difference in the cycle length-dependent QT and potassium currents in rabbits.|pdf=|usr=}}
| |
| − | {{tp|p=8355214|t=1993. Droperidol exerts dual effects on repolarization and induces early afterdepolarizations and triggered activity in rabbit Purkinje fibers.|pdf=|usr=}}
| |
| − | {{tp|p=15358992|t=2004. Magnesium homeostasis and antipsychotic-induced QTc prolongation.|pdf=|usr=}}
| |
| − | {{tp|p=14513929|t=2003. Antipsychotic induced prolongation of QTc interval treated with magnesium.|pdf=|usr=}}
| |
| − | {{tp|p=21677914|t=2011. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.|pdf=|usr=}}
| |
| − | {{tp|p=6471847|t=1984. EKG of the month. Torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=9140328|t=1997. Recurrent ventricular tachyarrhythmias associated with QT prolongation following hydrofluoric acid burns.|pdf=|usr=}}
| |
| − | {{tp|p=7837314|t=1995. Magnesium sulfate in the treatment of ventricular arrhythmias due to digoxin toxicity.|pdf=|usr=}}
| |
| − | {{tp|p=8230644|t=1993. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.|pdf=|usr=}}
| |
| − | {{tp|p=1749066|t=1991. Treatment of torsade de pointes with intravenous magnesium in idiopathic long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=8973383|t=1996. Effects of antiarrhythmic agents and Mg2+ on aconitine-induced arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=9057687|t=1996. Anticholinergic overdose induced torsade de pointes successfully treated with verapamil.|pdf=|usr=}}
| |
| − | {{tp|p=2724543|t=1989. Sheehan's syndrome with hypomagnesemia and polymorphous ventricular tachycardia.|pdf=|usr=}}
| |
| − | {{tp|p=7230515|t=1981. Etiology of QT prolongation and T wave changes in chronic alcoholism.|pdf=|usr=}}
| |
| − | {{tp|p=28294893|t=2016. [On Synergism of Potassium and Magnesium in Maintenance of Myocardial Function].|pdf=|usr=}}
| |
| − | {{tp|p=17495849|t=2007. [The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration].|pdf=|usr=}}
| |
| − | {{tp|p=1479796|t=1992. Atypische Form eines Long-QT-Syndroms--ein Fallbericht.|pdf=|usr=}}
| |
| − | {{tp|p=8256055|t=1993. [A case of life-threatening ventricular arrhythmias probably due to psychotropic drugs].|pdf=|usr=}}
| |
| − | {{tp|p=1325665|t=1992. [Antiarrhythmic effects of magnesium on single ventricular myocytes].|pdf=|usr=}}
| |
| − | {{tp|p=1348867|t=1992. [A case of congenital long QT syndrome associated with T wave alternans].|pdf=|usr=}}
| |
| − | {{tp|p=2047605|t=1991. [Efficacy of isoproterenol, magnesium sulfate and verapamil for torsade de pointes].|pdf=|usr=}}
| |
| − | {{tp|p=3532248|t=1986. [Clinical significance of QT interval].|pdf=|usr=}}
| |
| − | {{tp|p=8105332|t=1993. Does antiarrhythmic magnesium therapy enhance malarial infection?|pdf=|usr=}}
| |
| − | {{tp|p=31298598|t=2019. QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia.|pdf=|usr=}}
| |
| − | {{tp|p=7999530|t=1994. Antiarrhythmic effect of parenteral magnesium on ventricular tachycardia associated with long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=7999528|t=1994. Should magnesium therapy be considered for the treatment of coronary heart disease? I. A critical appraisal of current facts and hypotheses.|pdf=|usr=}}
| |
| − | {{tp|p=1296762|t=1992. New data on the antiarrhythmic value of parenteral magnesium treatment: magnesium and ventricular arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=2693848|t=1989. Magnesium therapy of cardiac arrhythmias in critical-care medicine.|pdf=|usr=}}
| |
| − | {{tp|p=3523053|t=1986. Magnesium and cardiac arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=15301336|t=2004. Acquired long QT syndrome and monomorphic ventricular tachycardia after alternative treatment with cesium chloride for brain cancer.|pdf=|usr=}}
| |
| − | {{tp|p=8189766|t=1994. Torsades de pointes ventricular tachycardia associated with overdose of astemizole.|pdf=|usr=}}
| |
| − | {{tp|p=28828702|t=2017. Vergiftungen mit psychotropen Substanzen.|pdf=|usr=}}
| |
| − | {{tp|p=27906148|t=2016. In brief: PPIs and Torsades de Pointes.|pdf=|usr=}}
| |
| − | {{tp|p=22970526|t=2012. Magnesium-Mangel und Arzneimittel.|pdf=|usr=}}
| |
| − | {{tp|p=15974204|t=2005. Bradycardia-associated torsade de pointes and the long-QT syndromes: a case report and review of the literature.|pdf=|usr=}}
| |
| − | {{tp|p=1407620|t=1992. Torsione di punta iatrogena indotta da tioridazina.|pdf=|usr=}}
| |
| − | {{tp|p=10783591|t=1999. Cisapride e rischio di complicanze cardiache.|pdf=|usr=}}
| |
| − | {{tp|p=11349326|t=2001. Herzrhythmusstorungen. Torsade de pointes durch Hypokaliamie.|pdf=|usr=}}
| |
| − | {{tp|p=8587608|t=1996. The inward rectification mechanism of the HERG cardiac potassium channel.|pdf=|usr=}}
| |
| − | {{tp|p=18648775|t=2008. An in vitro model for assessment of drug-induced torsade de pointes arrhythmia : effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia.|pdf=|usr=}}
| |
| − | {{tp|p=17093009|t=2007. Sudden cardiac death in nephrology: focus on acquired long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=12053061|t=2002. QT dispersion in renal transplant recipients.|pdf=|usr=}}
| |
| − | {{tp|p=9578069|t=1998. Effect of hemodialysis on the dispersion of the QTc interval.|pdf=|usr=}}
| |
| − | {{tp|p=17003569|t=2006. Blockade of renin-angiotensin system reduces QT dispersion and improves intracellular Ca/Mg status in hemodialysis patients.|pdf=|usr=}}
| |
| − | {{tp|p=16166802|t=2006. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis.|pdf=|usr=}}
| |
| − | {{tp|p=29923812|t=2018. The Identification of Torsades de Pointes via CEEG: A Case Report on a Patient with Physiologically Provoked Nonepileptic Events.|pdf=|usr=}}
| |
| − | {{tp|p=23452578|t=2013. QTc prolongation after brain surgery.|pdf=|usr=}}
| |
| − | {{tp|p=7993632|t=1994. Kir2.1 inward rectifier K+ channels are regulated independently by protein kinases and ATP hydrolysis.|pdf=|usr=}}
| |
| − | {{tp|p=18652879|t=2008. Elementary properties of Kir2.1, a strong inwardly rectifying K(+) channel expressed by pigeon vestibular type II hair cells.|pdf=|usr=}}
| |
| − | {{tp|p=18074575|t=2007. [Drug-induced long QT syndrome].|pdf=|usr=}}
| |
| − | {{tp|p=16001778|t=2005. [Long QT syndrome].|pdf=|usr=}}
| |
| − | {{tp|p=12136628|t=2002. [Drug-induced arrhythmias].|pdf=|usr=}}
| |
| − | {{tp|p=8810801|t=1996. [Drug-induced arrhythmias].|pdf=|usr=}}
| |
| − | {{tp|p=1685194|t=1991. [Torsade de pointes].|pdf=|usr=}}
| |
| − | {{tp|p=7476792|t=1994. Torsade de pointes and elevated magnesium and calcium requirements associated with intravenous pentamidine.|pdf=|usr=}}
| |
| − | {{tp|p=32086826|t=2020. Chemical cardioversion of atrial flutter and fibrillation in the pediatric population with Ibutilide.|pdf=|usr=}}
| |
| − | {{tp|p=27628760|t=2016. Provider Response to QTc Prolongation on Standard 12-Lead EKG: Do We Notice or Do We Care?|pdf=|usr=}}
| |
| − | {{tp|p=21039642|t=2013. Pregnancy and short-coupled torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=17976094|t=2007. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter.|pdf=|usr=}}
| |
| − | {{tp|p=16105013|t=2005. Effects of intravenous magnesium in a prolonged QT interval model of polymorphic ventricular tachycardia focus on transmural ventricular repolarization.|pdf=|usr=}}
| |
| − | {{tp|p=9604253|t=1998. Sotalol associated torsades de pointes tachycardia in a 15-month-old child: successful therapy with magnesium aspartate.|pdf=|usr=}}
| |
| − | {{tp|p=7681173|t=1993. Early afterdepolarization in a patient with complete atrioventricular block and torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=7690949|t=1993. Torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=1376904|t=1992. TU alternans, long QTU, and torsade de pointes: clinical and experimental observations.|pdf=|usr=}}
| |
| − | {{tp|p=1721131|t=1991. Association of humps on monophasic action potentials and ST-T alternans in a patient with Romano-Ward syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=1695751|t=1990. Magnesium therapy in ventricular arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=25701242|t=2015. Hypomagnesemic down-regulation of L-type Ca(2+) channel in cardiomyocyte as an arrhythmogenic substrate in rats.|pdf=|usr=}}
| |
| − | {{tp|p=11922507|t=2002. Studies of magnesium in congenital long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=7784240|t=1995. Effective use of magnesium for acquired torsade de pointes in a 4-month-old infant.|pdf=|usr=}}
| |
| − | {{tp|p=17251875|t=2007. Pilot study to determine the hemodynamic safety and feasibility of magnesium sulfate infusion in children with severe traumatic brain injury.|pdf=|usr=}}
| |
| − | {{tp|p=24694881|t=2014. Acquired long QT syndrome: a focus for the general pediatrician.|pdf=|usr=}}
| |
| − | {{tp|p=15094576|t=2004. Catecholaminergic polymorphic ventricular tachycardia: successful emergency treatment with intravenous propranolol.|pdf=|usr=}}
| |
| − | {{tp|p=8247942|t=1993. Torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=8488140|t=1993. Torsade de pointes associated with Astemizole overdose treated with magnesium sulfate.|pdf=|usr=}}
| |
| − | {{tp|p=16635167|t=2006. Successful uses of magnesium sulfate for torsades de pointes in children with long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=23760993|t=2013. QT and JT dispersion and cardiac performance in children with neonatal Bartter syndrome: a pilot study.|pdf=|usr=}}
| |
| − | {{tp|p=12837909|t=2003. Iatrogenic acute hypermagnesemia after total parenteral nutrition infusion mimicking septic shock syndrome: two case reports.|pdf=|usr=}}
| |
| − | {{tp|p=19002489|t=2009. Human Kir2.1 channel carries a transient outward potassium current with inward rectification.|pdf=|usr=}}
| |
| − | {{tp|p=9019734|t=1996. Heterooligomeric assembly of inward-rectifier K+ channels from subunits of different subfamilies: Kir2.1 (IRK1) and Kir4.1 (BIR10).|pdf=|usr=}}
| |
| − | {{tp|p=15918160|t=2005. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.|pdf=|usr=}}
| |
| − | {{tp|p=12076305|t=2002. Drug-induced ventricular tachyarrhythmia in isolated rabbit hearts with atrioventricular block.|pdf=|usr=}}
| |
| − | {{tp|p=29380488|t=2018. Validation and Clinical Utility of the hERG IC50:Cmax Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-Analysis.|pdf=|usr=}}
| |
| − | {{tp|p=29882591|t=2018. Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation: A Systematic Review.|pdf=|usr=}}
| |
| − | {{tp|p=17316157|t=2007. Management of dofetilide overdose in a patient with known cocaine abuse.|pdf=|usr=}}
| |
| − | {{tp|p=8643894|t=1996. Der klinisch-pharmakologische Fall (2).Bradykardie und ventrikulare Tachykardia vom Typ Torsade de pointes als Nebenwirkung von Vasopressin: drei Fallberichte.|pdf=|usr=}}
| |
| − | {{tp|p=7754271|t=1995. Magnesium in der Kardiologie.|pdf=|usr=}}
| |
| − | {{tp|p=3157959|t=1985. Torsades de pointes chez l'alcoolique.|pdf=|usr=}}
| |
| − | {{tp|p=3157953|t=1985. Traitement des torsades de pointes par le sulfate de magnesium.|pdf=|usr=}}
| |
| − | {{tp|p=12893979|t=2003. Why is the QT interval measurement so critical when evaluating an ECG rhythm?|pdf=|usr=}}
| |
| − | {{tp|p=16951992|t=2006. Effects of metal-binding properties of human Kv channel-interacting proteins on their molecular structure and binding with Kv4.2 channel.|pdf=|usr=}}
| |
| − | {{tp|p=19508229|t=2009. Functional roles of EF-hands in human potassium channel-interacting protein 2.2.|pdf=|usr=}}
| |
| − | {{tp|p=16901607|t=2006. Hypomagnesaemia causing QT interval prolongation and torsade de pointes in an alcoholic patient.|pdf=|usr=}}
| |
| − | {{tp|p=2326522|t=1990. Arritmia cardiaca grave secundaria a deplecion de magnesio. Torsade de pointe.|pdf=|usr=}}
| |
| − | {{tp|p=7209092|t=1980. Alternancia electrica de la onda T y "torsades de pointes".|pdf=|usr=}}
| |
| − | {{tp|p=23167136|t=2012. Le magnesium, applications en soins intensifs et en anesthesiologie.|pdf=|usr=}}
| |
| − | {{tp|p=31373450|t=2019. Torsade de pointe sur interaction medicamenteuse entre sotalol et ciprofloxacine.|pdf=|usr=}}
| |
| − | {{tp|p=28692217|t=2016. Le magnesium dans la pratique clinique quotidienne.|pdf=|usr=}}
| |
| − | {{tp|p=24024425|t=2013. Le QT long acquis.|pdf=|usr=}}
| |
| − | {{tp|p=2631832|t=1989. Eficacia terapeutica do sulfato de magnesio por via intravenosa em taquidisritmias. A proposito de quatro casos clinicos.|pdf=|usr=}}
| |
| − | {{tp|p=8497770|t=1993. Gefahrliche Rhythmusstorungen.|pdf=|usr=}}
| |
| − | {{tp|p=8421775|t=1993. Das "cardiac ballet" mit und ohne Amiodaron.|pdf=|usr=}}
| |
| − | {{tp|p=1699270|t=1990. Hemiparese und Torsade de pointes unter niedrigdosierter Therapie mit Sotalol.|pdf=|usr=}}
| |
| − | {{tp|p=3070741|t=1988. Magnesium in der Kardiologie. Grundlagen und mogliche Indikationen.|pdf=|usr=}}
| |
| − | {{tp|p=30620510|t=2016. [Long QT Syndrome Induced by Antidepressants].|pdf=|usr=}}
| |
| − | {{tp|p=9459289|t=1998. Hypomagnesemia: renal magnesium handling.|pdf=|usr=}}
| |
| − | {{tp|p=10709414|t=1999. Electrocardiographic case: a middle aged, seriously ill woman with an unusual ECG and wide complex tachycardia.|pdf=|usr=}}
| |
| − | {{tp|p=8266190|t=1993. Torsade de pointes and sudden death associated with diabetic autonomic diarrhoea--a case report.|pdf=|usr=}}
| |
| − | {{tp|p=11811859|t=2001. Magnesium: its proven and potential clinical significance.|pdf=|usr=}}
| |
| − | {{tp|p=10586828|t=1999. Magnesium for the next millennium.|pdf=|usr=}}
| |
| − | {{tp|p=9042182|t=1997. Hyperphosphatemia associated with phosphorus-containing laxatives in a patient with chronic renal insufficiency.|pdf=|usr=}}
| |
| − | {{tp|p=14963284|t=2004. Electrocardiographic abnormalities and serum magnesium in patients with subarachnoid hemorrhage.|pdf=|usr=}}
| |
| − | {{tp|p=19418112|t=2009. QT interval prolongation among patients treated with angiogenesis inhibitors.|pdf=|usr=}}
| |
| − | {{tp|p=8091345|t=1993. Pathologie cardiovasculaire et magnesium.|pdf=|usr=}}
| |
| − | {{tp|p=2094063|t=1990. Effect of magnesium sulfate on ventricular refractoriness and its efficacy for torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=18067651|t=2007. Assessment of corrected QT interval in sickle-cell disease patients who undergo erythroapheresis.|pdf=|usr=}}
| |
| − | {{tp|p=20620555|t=2010. Torsades de pointes triggered by severe diastolic hypotension with low hematocrit in the neohepatic stage of liver transplantation: a case report.|pdf=|usr=}}
| |
| − | {{tp|p=10770105|t=1999. Torsade de pointes associated with encephalitis.|pdf=|usr=}}
| |
| − | {{tp|p=8701528|t=1996. Torsade de pointes-takykardi ved sotalolbehandling af en normokaliaemisk patient.|pdf=|usr=}}
| |
| − | {{tp|p=15287289|t=2004. Eclampsia and abnormal QTc.|pdf=|usr=}}
| |
| − | {{tp|p=18365152|t=2008. Medikamentos induzierte Verlangerung des QT-Intervalls.|pdf=|usr=}}
| |
| − | {{tp|p=11105328|t=2000. Der Stellenwert von Magnesium bei Herzrhythmusstorungen.|pdf=|usr=}}
| |
| − | {{tp|p=27878411|t=2018. Riskante Gabe von QT-Intervall-verlangernden Wirkstoffen bei alteren Patienten mit arzneimittelinduzierter Torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=9064959|t=1996. Magnesium: Aktuelle Studien--kritische Wertung--Konsequenzen.|pdf=|usr=}}
| |
| − | {{tp|p=9064958|t=1996. Magnesium als antiarrhythmisches Therapieprinzip bei supraventrikularen und ventrikularen Herzrhythmusstorungen.|pdf=|usr=}}
| |
| − | {{tp|p=7502575|t=1995. Sotalol-induzierte Torsade-de-Pointes-Tachykardien bei einem 15 Monate alten Kleinkind.|pdf=|usr=}}
| |
| − | {{tp|p=7863684|t=1994. Die Bedeutung von Magnesium in der Intensivmedizin.|pdf=|usr=}}
| |
| − | {{tp|p=8147050|t=1993. Torsade de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=29926671|t=2018. [Anti-arrhythmic effects of taurine-magnesium coordination compound on torsades de pointes].|pdf=|usr=}}
| |
| − | {{tp|p=8404313|t=1993. [Classification and treatment of torsades de pointes (TdP): a report of 11 cases].|pdf=|usr=}}
| |
| − | {{tp|p=21624302|t=2011. [Clinical characteristics and outcome of 32 patients with long-QT syndrome accompanied with torsade de pointes].|pdf=|usr=}}
| |
| − | {{tp|p=21624301|t=2011. [Clinical characteristics of 52 patients with torsade de points associated with acquired QT prolongation].|pdf=|usr=}}
| |
| − | {{tp|p=17386161|t=2007. [The effects of calmodulin kinase II inhibitor on ventricular arrhythmias in rabbits with cardiac hypertrophy].|pdf=|usr=}}
| |
| − | {{tp|p=15932674|t=2005. [Calmodulin antagonist inhibits torsade de pointes induced by d-sotalol in an isolated rabbit heart model].|pdf=|usr=}}
| |
| − | {{tp|p=8854446|t=1995. Acquired long QT syndrome in a child undergoing craniotomy: a case report.|pdf=|usr=}}
| |
| | | | |
| − |
| |
| − |
| |
| − | {{bibi|TI=Mg - HCQ|S1=%22mg2%2B%22+OR+magnesium+OR+mgso4+OR+hypomagnes*+OR+hypermagnes*+OR+trpm7|S2=chloroquine+OR+hydroxychloroquine|S3=|dPMID=08/05/20|dPMC=----}}
| |
| − | {{tp|p=22987900|t=2012. Severe primary hypothyroidism presenting with torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=23203174|t=2012. Syncope in a patient being treated for hepatic and intestinal amoebiasis.|pdf=|usr=}}
| |
| − | {{tp|p=26351590|t=2015. Novel Therapies for Myocardial Irritability following Extreme Hydroxychloroquine Toxicity.|pdf=|usr=}}
| |
| − | {{tp|p=14342342|t=1965. SPECTROPHOTOMETRIC STUDIES OF THE INTERACTION OF CHLOROQUINE WITH DEOXYRIBONUCLEIC ACID.|pdf=|usr=}}
| |
| − | {{tp|p=32650197|t=2020. Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole.|pdf=|usr=}}
| |
| − | {{tp|p=673850|t=1978. The inhibition of mitochondrial DNA polymerase gamma from animal cells by intercalating drugs.|pdf=|usr=}}
| |
| − | {{tp|p=14982575|t=2004. Massive hydroxychloroquine overdose.|pdf=|usr=}}
| |
| − | {{tp|p=6818843|t=1982. Weak-base induced lysosomal secretion by macrophages: an alternative trigger mechanism that is independent of complement activation.|pdf=|usr=}}
| |
| − | {{tp|p=7977698|t=1994. Loss of red blood cell glutathione during Mg deficiency: prevention by vitamin E, D-propranolol, and chloroquine.|pdf=|usr=}}
| |
| − | {{tp|p=8460675|t=1993. Modulation of cytokines and myocardial lesions by vitamin E and chloroquine in a Mg-deficient rat model.|pdf=|usr=}}
| |
| − | {{tp|p=14067478|t=1963. THE RESPONSE OF HYPERCALCEMIA IN SARCOIDOSIS TO CHLOROQUINE.|pdf=|usr=}}
| |
| − | {{tp|p=2960325|t=1987. Inhibition of calmodulin stimulation of phosphodiesterase and Ca2+, Mg2+-ATPase activities and shape change of erythrocyte ghosts by chloroquine.|pdf=|usr=}}
| |
| − | {{tp|p=2990487|t=1985. Inhibition of phosphatidylinositol phosphodiesterase activity in skeletal muscle by metal ions and drugs which block neuromuscular transmission.|pdf=|usr=}}
| |
| − | {{tp|p=4312459|t=1969. Chloroquine and synthesis of aminoacyl transfer ribonucleic acids. Conformational changes in tryptophanyl and tryptophan transfer ribonucleic acids.|pdf=|usr=}}
| |
| − | {{tp|p=2831987|t=1988. Studies on the interaction of 4-quinolones with DNA by DNA unwinding experiments.|pdf=|usr=}}
| |
| − | {{tp|p=4569158|t=1972. The inhibition in vitro of bacterial DNA polymerases and RNA polymerase by antimalarial 8-aminoquinolines and by chloroquine.|pdf=|usr=}}
| |
| − | {{tp|p=5750458|t=1968. Comparison of chloroquine binding to DNA, and polyadenylic and polyguanylic acids.|pdf=|usr=}}
| |
| − | {{tp|p=18538567|t=2008. Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.|pdf=|usr=}}
| |
| − | {{tp|p=16842209|t=2006. Antiplatelet and antileukocyte effects of cardiovascular, immunomodulatory and chemotherapeutic drugs.|pdf=|usr=}}
| |
| − | {{tp|p=4966073|t=1966. Chloroquine-mediated conversion of transfer ribonucleic acid of Escherichia coli from an inactive to an active state.|pdf=|usr=}}
| |
| − | {{tp|p=15038247|t=2004. Treatment with antimalarials adversely affects the oxidative energy metabolism in rat liver mitochondria.|pdf=|usr=}}
| |
| − | {{tp|p=3556432|t=1987. Control of membrane permeability in animal cells by divalent cations.|pdf=|usr=}}
| |
| − | {{tp|p=7895830|t=1995. Plasmodium falciparum and Plasmodium berghei: effect of magnesium on the development of parasitemia.|pdf=|usr=}}
| |
| − | {{tp|p=3905702|t=1985. Effects of chloroquine on the serum complement system.|pdf=|usr=}}
| |
| − | {{tp|p=11103308|t=2000. Distribution of key ions of chloroquine biotransformation and cholesterol uptake in rat liver.|pdf=|usr=}}
| |
| − | {{tp|p=1359089|t=1992. Adsorption of paracetamol and chloroquine phosphate by some antacids.|pdf=|usr=}}
| |
| − | {{tp|p=6292443|t=1982. The effect of magnesium trisilicate and kaolin on the in vivo absorption of chloroquine.|pdf=|usr=}}
| |
| − | {{tp|p=2460697|t=1988. Inhibition of adsorptive endocytosis and transcytosis in pulmonary microvessels.|pdf=|usr=}}
| |
| − | {{tp|p=7382912|t=1980. Inhibition of hepatitis B virus specific DNA polymerase by intercalating agents.|pdf=|usr=}}
| |
| − | {{tp|p=10497894|t=1999. The effect of binding of chlorpromazine and chloroquine to ion transporting ATPases.|pdf=|usr=}}
| |
| − | {{tp|p=5460005|t=1970. The effect of chloroquine on the enzymatic hydrolysis of nucleic acids.|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | {{bibi|TI=HCQ - QTc|S1=chloroquine+OR+hydroxychloroquine|S2=QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+QT+time+OR+QT+prolongation+OR+QT+dispersion+OR+OR+lqt*+OR+long+qt+OR+early+afterdepolari*+OR+early+after-depolari*+OR+torsade+de+pointes+OR+%22kir2.1%22+OR+%22kv4.2%22+OR+hERG|S3=|dPMID=08/05/20|dPMC=08/05/2020}}
| |
| − |
| |
| − | {{tp|p=32383430|t=2020. Case Report: Right Bundle Brunch Block and QTc Prolongation in a Patient with COVID-19 Treated with Hydroxychloroquine.|pdf=|usr=}}
| |
| − | {{tp|p=22391528|t=2012. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials.|pdf=|usr=}}
| |
| − | {{tp|p=32354666|t=2020. Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.|pdf=|usr=}}
| |
| − | {{tp|p=32331979|t=2020. Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.|pdf=|usr=}}
| |
| − | {{tp|p=32638906|t=2020. Controle do Intervalo QT para Prevencao de Torsades de Pointes Durante uso de Hidroxicloroquina e/ou Azitromicina em Pacientes com COVID 19.|pdf=|usr=}}
| |
| − | {{tp|p=30835490|t=2019. Electrophysiological and Pharmacological Characterization of Human Inwardly Rectifying Kir2.1 Channels on an Automated Patch-Clamp Platform.|pdf=|usr=}}
| |
| − | {{tp|p=22369270|t=2012. QT dispersion in patients with systemic lupus erythematosus: the impact of disease activity.|pdf=|usr=}}
| |
| − | {{tp|p=30400791|t=2018. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review.|pdf=|usr=}}
| |
| − | {{tp|p=22987900|t=2012. Severe primary hypothyroidism presenting with torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=23203174|t=2012. Syncope in a patient being treated for hepatic and intestinal amoebiasis.|pdf=|usr=}}
| |
| − | {{tp|p=32350872|t=2020. COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?|pdf=|usr=}}
| |
| − | {{tp|p=23701202|t=2013. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.|pdf=|usr=}}
| |
| − | {{tp|p=32299753|t=2020. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.|pdf=|usr=}}
| |
| − | {{tp|p=32686633|t=2020. QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019.|pdf=|usr=}}
| |
| − | {{tp|p=21233253|t=2011. Structural bases for the different anti-fibrillatory effects of chloroquine and quinidine.|pdf=|usr=}}
| |
| − | {{tp|p=27478650|t=2016. Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine.|pdf=|usr=}}
| |
| − | {{tp|p=19710529|t=2009. Chloroquine blocks a mutant Kir2.1 channel responsible for short QT syndrome and normalizes repolarization properties in silico.|pdf=|usr=}}
| |
| − | {{tp|p=32347743|t=2020. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.|pdf=|usr=}}
| |
| − | {{tp|p=32588427|t=2020. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.|pdf=|usr=}}
| |
| − | {{tp|p=32285930|t=2020. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.|pdf=|usr=}}
| |
| − | {{tp|p=32626630|t=2020. Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review.|pdf=|usr=}}
| |
| − | {{tp|p=32605683|t=2020. Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas.|pdf=|usr=}}
| |
| − | {{tp|p=32372695|t=2020. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.|pdf=|usr=}}
| |
| − | {{tp|p=32356580|t=2020. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.|pdf=|usr=}}
| |
| − | {{tp|p=20585026|t=2010. Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets.|pdf=|usr=}}
| |
| − | {{tp|p=31827438|t=2019. The Antimalarial Chloroquine Reduces the Burden of Persistent Atrial Fibrillation.|pdf=|usr=}}
| |
| − | {{tp|p=32387247|t=2020. Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019.|pdf=|usr=}}
| |
| − | {{tp|p=32380291|t=2020. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.|pdf=|usr=}}
| |
| − | {{tp|p=32479900|t=2020. Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32407884|t=2020. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.|pdf=|usr=}}
| |
| − | {{tp|p=32438018|t=2020. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.|pdf=|usr=}}
| |
| − | {{tp|p=32610165|t=2020. Effects of hydroxychloroquine treatment on QT interval.|pdf=|usr=}}
| |
| − | {{tp|p=32622993|t=2020. Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk.|pdf=|usr=}}
| |
| − | {{tp|p=32621881|t=2020. Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection, including drug-induced changes in the corrected QT interval.|pdf=|usr=}}
| |
| − | {{tp|p=32302703|t=2020. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.|pdf=|usr=}}
| |
| − | {{tp|p=32676695|t=2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.|pdf=|usr=}}
| |
| − | {{tp|p=32363145|t=2020. An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine.|pdf=|usr=}}
| |
| − | {{tp|p=24958937|t=2014. Ciprofloxacin-Induced Syndrome of Inappropriate Antidiuretic Hormone; Anaphylactic Shock Due to Thrombolytic Administration; Hydroxychloroquine-Induced QT-Interval Prolongation; Complex Regional Pain Syndrome After Tetanus Toxoid Injection.|pdf=|usr=}}
| |
| − | {{tp|p=32278018|t=2020. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society.|pdf=|usr=}}
| |
| − | {{tp|p=32621997|t=2020. Which QTc correction formulae (Bazett, Framingham, or Fridericia) to use for Hydroxychloroquine induced QTc prolongation?|pdf=|usr=}}
| |
| − | {{tp|p=32621996|t=2020. HCQ induced QT prolongation- Primum non nocere.|pdf=|usr=}}
| |
| − | {{tp|p=32534189|t=2020. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.|pdf=|usr=}}
| |
| − | {{tp|p=32439366|t=2020. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin.|pdf=|usr=}}
| |
| − | {{tp|p=32623082|t=2020. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32624690|t=2020. Cardiovascular disease management during the coronavirus disease 2019 pandemic.|pdf=|usr=}}
| |
| − | {{tp|p=32627127|t=2020. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.|pdf=|usr=}}
| |
| − | {{tp|p=32283123|t=2020. Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment.|pdf=|usr=}}
| |
| − | {{tp|p=32407770|t=2020. COVID-19, Clinical Trials, and QT-Prolonging Prophylactic Therapy in Healthy Subjects: First, Do No Harm.|pdf=|usr=}}
| |
| − | {{tp|p=32463348|t=2020. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.|pdf=|usr=}}
| |
| − | {{tp|p=32463308|t=2020. Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?|pdf=|usr=}}
| |
| − | {{tp|p=11960982|t=2002. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.|pdf=|usr=}}
| |
| − | {{tp|p=32753328|t=2020. Torsades de Pointes in Coronavirus Disease 2019 Infection.|pdf=|usr=}}
| |
| − | {{tp|p=32485061|t=2020. Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin.|pdf=|usr=}}
| |
| − | {{tp|p=32549293|t=2020. A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation.|pdf=|usr=}}
| |
| − | {{tp|p=32731139|t=2020. Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=27173501|t=2016. Quinine and the ABCs of Long QT: A Patient's Misfortune with Arthritis, (Alcoholic) Beverages, and Cramps.|pdf=|usr=}}
| |
| − | {{tp|p=32474031|t=2020. Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.|pdf=|usr=}}
| |
| − | {{tp|p=32418181|t=2020. Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.|pdf=|usr=}}
| |
| − | {{tp|p=32494896|t=2020. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.|pdf=|usr=}}
| |
| − | {{tp|p=32654098|t=2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.|pdf=|usr=}}
| |
| − | {{tp|p=19285083|t=2009. Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=23759957|t=2013. Assessment of proarrhythmic activity of chloroquine in in vivo and ex vivo rabbit models.|pdf=|usr=}}
| |
| − | {{tp|p=32392282|t=2020. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.|pdf=|usr=}}
| |
| − | {{tp|p=32356863|t=2020. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).|pdf=|usr=}}
| |
| − | {{tp|p=26818020|t=2016. Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study.|pdf=|usr=}}
| |
| − | {{tp|p=32359771|t=2020. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).|pdf=|usr=}}
| |
| − | {{tp|p=32442941|t=2020. Hidroxicloroquina. Mensajes desde la cardiologia en tiempos de pandemia por coronavirus.|pdf=|usr=}}
| |
| − | {{tp|p=32511528|t=2020. Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions.|pdf=|usr=}}
| |
| − | {{tp|p=32648153|t=2020. The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine.|pdf=|usr=}}
| |
| − | {{tp|p=32643072|t=2020. An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation.|pdf=|usr=}}
| |
| − | {{tp|p=32350818|t=2020. Chloroquine-induced QTc prolongation in COVID-19 patients.|pdf=|usr=}}
| |
| − | {{tp|p=29290967|t=2017. Modelling the effects of chloroquine on KCNJ2-linked short QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=32654931|t=2020. Hydroxychloroquine and the treatment of Sjogren syndrome, chronic ulcerative stomatitis, and oral lichen planus in the age of COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=17213921|t=2007. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers.|pdf=|usr=}}
| |
| − | {{tp|p=32701969|t=2020. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.|pdf=|usr=}}
| |
| − | {{tp|p=11320287|t=2001. Recurrent syncope. Drug induced long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=32441496|t=2020. The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.|pdf=|usr=}}
| |
| − | {{tp|p=18216262|t=2008. The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel.|pdf=|usr=}}
| |
| − | {{tp|p=32327397|t=2020. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.|pdf=|usr=}}
| |
| − | {{tp|p=32501367|t=2020. Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations.|pdf=|usr=}}
| |
| − | {{tp|p=32694915|t=2020. Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen.|pdf=|usr=}}
| |
| − | {{tp|p=32457932|t=2020. Chloroquine, hydroxychloroquine and COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32503662|t=2020. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.|pdf=|usr=}}
| |
| − | {{tp|p=32493478|t=2020. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.|pdf=|usr=}}
| |
| − | {{tp|p=32493468|t=2020. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.|pdf=|usr=}}
| |
| − | {{tp|p=32736597|t=2020. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.|pdf=|usr=}}
| |
| − | {{tp|p=32616063|t=2020. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.|pdf=|usr=}}
| |
| − | {{tp|p=32665039|t=2020. Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada.|pdf=|usr=}}
| |
| − | {{tp|p=32395788|t=2020. Features of patients with 2019 novel coronavirus admitted in a pneumology department: The first retrospective Tunisian case series.|pdf=|usr=}}
| |
| − | {{tp|p=17984356|t=2007. Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig.|pdf=|usr=}}
| |
| − | {{tp|p=12363064|t=2002. The effects of antimalarial drugs on ventricular repolarization.|pdf=|usr=}}
| |
| − | {{tp|p=31907183|t=2020. High-Dose Chloroquine for Uncomplicated Plasmodium falciparum Malaria Is Well Tolerated and Causes Similar QT Interval Prolongation as Standard-Dose Chloroquine in Children.|pdf=|usr=}}
| |
| − | {{tp|p=32523150|t=2020. Potenciales efectos pro-arritmicos de la farmacoterapia contra SARS-CoV-2.|pdf=|usr=}}
| |
| − | {{tp|p=8267504|t=1993. Les tachycardies ventriculaires d'origine medicamenteuse.|pdf=|usr=}}
| |
| − | {{tp|p=30738635|t=2019. Fetal dysrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=18182162|t=2008. Lysosome mediated Kir2.1 breakdown directly influences inward rectifier current density.|pdf=|usr=}}
| |
| − | {{tp|p=32687645|t=2020. Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.|pdf=|usr=}}
| |
| − | {{tp|p=32267732|t=2020. Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.|pdf=|usr=}}
| |
| − | {{tp|p=16615675|t=2006. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.|pdf=|usr=}}
| |
| − | {{tp|p=30441573|t=2018. Computational Analysis of the Action of Chloroquine on Short QT Syndrome Variant 1 and Variant 3 in Human Ventricles.|pdf=|usr=}}
| |
| − | {{tp|p=28216048|t=2017. Chloroquine blocks the Kir4.1 channels by an open-pore blocking mechanism.|pdf=|usr=}}
| |
| − | {{tp|p=14729380|t=2004. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.|pdf=|usr=}}
| |
| − | {{tp|p=32693652|t=2020. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.|pdf=|usr=}}
| |
| − | {{tp|p=16352079|t=2002. Antimalarial drugs inhibit the acetylcholine-receptor-operated potassium current in atrial myocytes.|pdf=|usr=}}
| |
| − | {{tp|p=23409733|t=2013. Chloroquine cardiotoxicity mimicking connective tissue disease heart involvement.|pdf=|usr=}}
| |
| − | {{tp|p=17590456|t=2008. Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine.|pdf=|usr=}}
| |
| − | {{tp|p=3183189|t=1988. Protective cardiovascular effects of diazepam in experimental acute chloroquine poisoning.|pdf=|usr=}}
| |
| − | {{tp|p=32750131|t=2020. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.|pdf=|usr=}}
| |
| − | {{tp|p=32700555|t=2020. Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.|pdf=|usr=}}
| |
| − | {{tp|p=23872551|t=2013. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus.|pdf=|usr=}}
| |
| − | {{tp|p=25654185|t=2015. Antimalarial activity of 4-amidinoquinoline and 10-amidinobenzonaphthyridine derivatives.|pdf=|usr=}}
| |
| − | {{tp|p=32534369|t=2020. Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma.|pdf=|usr=}}
| |
| − | {{tp|p=19654266|t=2009. Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions.|pdf=|usr=}}
| |
| − | {{tp|p=7629906|t=1995. The hazards of chloroquine self prescription in west Africa.|pdf=|usr=}}
| |
| − | {{tp|p=31776555|t=2020. Drug interactions with antimalarial medications in older travelers: a clinical guide.|pdf=|usr=}}
| |
| − | {{tp|p=32356857|t=2020. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation.|pdf=|usr=}}
| |
| − | {{tp|p=24360369|t=2014. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.|pdf=|usr=}}
| |
| − | {{tp|p=17646028|t=2007. Cardiotoxicity of antimalarial drugs.|pdf=|usr=}}
| |
| − | {{tp|p=32706953|t=2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.|pdf=|usr=}}
| |
| − | {{tp|p=32488217|t=2020. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.|pdf=|usr=}}
| |
| − | {{tp|p=12494620|t=2002. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers.|pdf=|usr=}}
| |
| − | {{tp|p=23192368|t=2013. Inhibiting the clathrin-mediated endocytosis pathway rescues K(IR)2.1 downregulation by pentamidine.|pdf=|usr=}}
| |
| − | {{tp|p=21125143|t=2010. Arrhythmias in systemic lupus erythematosus.|pdf=|usr=}}
| |
| − |
| |
| − | '''PMC'''
| |
| − |
| |
| − |
| |
| − | {{tp|p=21615117|t=2011. Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133.|pdf=|usr=}}
| |
| − | {{tp|p=23685953|t=2013. Inside job: ligand-receptor pharmacology beneath the plasma membrane.|pdf=|usr=}}
| |
| − | {{tp|p=32517786|t=2020. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.|pdf=|usr=}}
| |
| − | {{tp|p=29937880|t=2017. QTc prolongation in Black diabetic subjects with cardiac autonomic neuropathy.|pdf=|usr=}}
| |
| − | {{tp|p=32497913|t=2020. A current review of COVID-19 for the cardiovascular specialist.|pdf=|usr=}}
| |
| − | {{tp|p=32624192|t=2020. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32425199|t=2020. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.|pdf=|usr=}}
| |
| − | {{tp|p=25006531|t=2014. Gold nanoparticle-spermidine complex blocks the inward rectifier potassium channel.|pdf=|usr=}}
| |
| − | {{tp|p=32737841|t=2020. Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?|pdf=|usr=}}
| |
| − | {{tp|p=32336586|t=2020. Pharmacotherapy in COVID-19; A narrative review for emergency providers.|pdf=|usr=}}
| |
| − | {{tp|p=24731243|t=2014. Autologous dendritic cells prolong allograft survival through Tmem176b-dependent antigen cross-presentation.|pdf=|usr=}}
| |
| − | {{tp|p=32247318|t=2020. A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).|pdf=|usr=}}
| |
| − | {{tp|p=32425051|t=2020. Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial.|pdf=|usr=}}
| |
| − | {{tp|p=32232419|t=2020. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.|pdf=|usr=}}
| |
| − | {{tp|p=24597863|t=2014. Assessment of inhomogeneities of repolarization in patients with systemic lupus erythematosus.|pdf=|usr=}}
| |
| − | {{tp|p=16699058|t=2006. Effects of acute administration of iloprost on the cardiac autonomic nervous system and ventricular repolarisation in patients with systemic sclerosis.|pdf=|usr=}}
| |
| − | {{tp|p=22615288|t=2012. High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis.|pdf=|usr=}}
| |
| − | {{tp|p=32571633|t=2020. Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials.|pdf=|usr=}}
| |
| − | {{tp|p=32675039|t=2020. Hydroxychloroquine and Potential Drug Interactions in Older Adults.|pdf=|usr=}}
| |
| − | {{tp|p=32354666|t=2020. Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.|pdf=|usr=}}
| |
| − | {{tp|p=32740801|t=2020. Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=31463053|t=2019. British Heart Rhythm Society Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic Medication.|pdf=|usr=}}
| |
| − | {{tp|p=22364570|t=2012. Contributions of mass spectrometry-based proteomics to defining cellular mechanisms and diagnostic markers for systemic lupus erythematosus.|pdf=|usr=}}
| |
| − | {{tp|p=32446195|t=2020. Interactions of recommended COVID-19 drugs with commonly used psychotropics.|pdf=|usr=}}
| |
| − | {{tp|p=32398343|t=2020. Should azithromycin be used to treat COVID-19? A rapid review.|pdf=|usr=}}
| |
| − | {{tp|p=32664944|t=2020. Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.|pdf=|usr=}}
| |
| − | {{tp|p=30400791|t=2018. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review.|pdf=|usr=}}
| |
| − | {{tp|p=32409561|t=2020. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.|pdf=|usr=}}
| |
| − | {{tp|p=32409486|t=2020. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.|pdf=|usr=}}
| |
| − | {{tp|p=32169926|t=2020. Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register-based cohort study.|pdf=|usr=}}
| |
| − | {{tp|p=28601826|t=2017. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours.|pdf=|usr=}}
| |
| − | {{tp|p=32384171|t=2020. COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions.|pdf=|usr=}}
| |
| − | {{tp|p=26183037|t=2016. Pharmacological treatment of acquired QT prolongation and torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=23167578|t=2013. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.|pdf=|usr=}}
| |
| − | {{tp|p=20642543|t=2010. Drug- and non-drug-associated QT interval prolongation.|pdf=|usr=}}
| |
| − | {{tp|p=19076152|t=2009. Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study.|pdf=|usr=}}
| |
| − | {{tp|p=16869820|t=2007. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs.|pdf=|usr=}}
| |
| − | {{tp|p=12207642|t=2002. The significance of QT interval in drug development.|pdf=|usr=}}
| |
| − | {{tp|p=12207637|t=2002. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries.|pdf=|usr=}}
| |
| − | {{tp|p=11966667|t=2002. Non-sedating antihistamine drugs and cardiac arrhythmias -- biased risk estimates from spontaneous reporting systems?|pdf=|usr=}}
| |
| − | {{tp|p=3741724|t=1986. Cardiovascular toxicity and distribution kinetics of intravenous chloroquine.|pdf=|usr=}}
| |
| − | {{tp|p=16474415|t=2006. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.|pdf=|usr=}}
| |
| − | {{tp|p=15655517|t=2005. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres.|pdf=|usr=}}
| |
| − | {{tp|p=12839862|t=2003. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.|pdf=|usr=}}
| |
| − | {{tp|p=12839860|t=2003. Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine.|pdf=|usr=}}
| |
| − | {{tp|p=29924137|t=2018. Strontium ranelate as a possible disease-modifying osteoarthritis drug: a systematic review.|pdf=|usr=}}
| |
| − | {{tp|p=32537248|t=2020. Mechanisms of Myocardial Injury in Coronavirus Disease 2019.|pdf=|usr=}}
| |
| − | {{tp|p=18651395|t=2008. Drug-induced spatial dispersion of repolarization.|pdf=|usr=}}
| |
| − | {{tp|p=32557011|t=2020. A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.|pdf=|usr=}}
| |
| − | {{tp|p=32671601|t=2020. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.|pdf=|usr=}}
| |
| − | {{tp|p=26351590|t=2015. Novel Therapies for Myocardial Irritability following Extreme Hydroxychloroquine Toxicity.|pdf=|usr=}}
| |
| − | {{tp|p=32123164|t=2020. Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K.|pdf=|usr=}}
| |
| − | {{tp|p=32629149|t=2020. Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=27540685|t=2017. Styrax blocks inward and outward current of Kir2.1 channel.|pdf=|usr=}}
| |
| − | {{tp|p=26556552|t=2015. Cardiac ion channels.|pdf=|usr=}}
| |
| − | {{tp|p=23221912|t=2013. Role of the activation gate in determining the extracellular potassium dependency of block of HERG by trapped drugs.|pdf=|usr=}}
| |
| − | {{tp|p=32436730|t=2020. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.|pdf=|usr=}}
| |
| − | {{tp|p=32434385|t=2020. Cardiac Arrhythmias in COVID-19 Infection.|pdf=|usr=}}
| |
| − | {{tp|p=23449547|t=2013. Rotors and the dynamics of cardiac fibrillation.|pdf=|usr=}}
| |
| − | {{tp|p=32228309|t=2020. Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association.|pdf=|usr=}}
| |
| − | {{tp|p=32442023|t=2020. Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database.|pdf=|usr=}}
| |
| − | {{tp|p=20142454|t=2010. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.|pdf=|usr=}}
| |
| − | {{tp|p=32438948|t=2020. Just the facts: What drugs are safe and effective for COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32468425|t=2020. An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19).|pdf=|usr=}}
| |
| − | {{tp|p=32533455|t=2020. Azithromycin for COVID-19: More Than Just an Antimicrobial?|pdf=|usr=}}
| |
| − | {{tp|p=25572282|t=2015. Population-based study of QT interval prolongation in patients with rheumatoid arthritis.|pdf=|usr=}}
| |
| − | {{tp|p=29497521|t=2012. Episodic electrolyte disorders and renal failure due to a rare disease: the McKittrick-Wheelock syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=26833512|t=2016. Sarcoidosis of the cardio-pulmonary systems.|pdf=|usr=}}
| |
| − | {{tp|p=32422406|t=2020. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32306288|t=2020. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.|pdf=|usr=}}
| |
| − | {{tp|p=32302411|t=2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32495226|t=2020. Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?|pdf=|usr=}}
| |
| − | {{tp|p=32268005|t=2020. Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection.|pdf=|usr=}}
| |
| − | {{tp|p=32401962|t=2020. Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32269021|t=2020. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.|pdf=|usr=}}
| |
| − | {{tp|p=30962197|t=2019. Use of vitamin D drops leading to kidney failure in a 54-year-old man.|pdf=|usr=}}
| |
| − | {{tp|p=29957821|t=2018. Immunosuppressive treatment for proliferative lupus nephritis.|pdf=|usr=}}
| |
| − | {{tp|p=21328286|t=2011. Azithromycin for treating uncomplicated malaria.|pdf=|usr=}}
| |
| − | {{tp|p=32384908|t=2020. Chloroquine for COVID-19: rationale, facts, hopes.|pdf=|usr=}}
| |
| − | {{tp|p=32653015|t=2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.|pdf=|usr=}}
| |
| − | {{tp|p=32467423|t=2020. Potential mechanisms of cardiac injury and common pathways of inflammation in patients with COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32626630|t=2020. Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review.|pdf=|usr=}}
| |
| − | {{tp|p=32550090|t=2020. Bradycardia in Patients With COVID-19: A Calm Before the Storm?|pdf=|usr=}}
| |
| − | {{tp|p=32318865|t=2020. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response.|pdf=|usr=}}
| |
| − | {{tp|p=24721648|t=2014. Cardiac and renal inward rectifier potassium channel pharmacology: emerging tools for integrative physiology and therapeutics.|pdf=|usr=}}
| |
| − | {{tp|p=32395418|t=2020. An Update on Current Therapeutic Drugs Treating COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=24944403|t=2003. Analysis of West Virginia medicaid claims data for the prevalence of medical conditions and use of drugs likely to cause QT prolongation in patients with schizophrenia.|pdf=|usr=}}
| |
| − | {{tp|p=32417708|t=2020. "Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis."|pdf=|usr=}}
| |
| − | {{tp|p=31835542|t=2019. Arrhythmogenic Inflammatory Cardiomyopathy in Autoimmune Rheumatic Diseases: A Challenge for Cardio-Rheumatology.|pdf=|usr=}}
| |
| − | {{tp|p=32696429|t=2020. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.|pdf=|usr=}}
| |
| − | {{tp|p=31844421|t=2019. Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues.|pdf=|usr=}}
| |
| − | {{tp|p=25749803|t=2015. Use of adjectives in abstracts when reporting results of randomized, controlled trials from industry and academia.|pdf=|usr=}}
| |
| − | {{tp|p=21468196|t=2010. A practical approach to genetic hypokalemia.|pdf=|usr=}}
| |
| − | {{tp|p=32369020|t=2020. The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection.|pdf=|usr=}}
| |
| − | {{tp|p=8617203|t=1996. Complementation between kinase-defective and activation-defective TGF-beta receptors reveals a novel form of receptor cooperativity essential for signaling.|pdf=|usr=}}
| |
| − | {{tp|p=32378805|t=2020. COVID-19 and toxicity from potential treatments: Panacea or poison.|pdf=|usr=}}
| |
| − | {{tp|p=32338155|t=2020. Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32562486|t=2020. COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests.|pdf=|usr=}}
| |
| − | {{tp|p=24062937|t=2013. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review.|pdf=|usr=}}
| |
| − | {{tp|p=32347923|t=2020. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety.|pdf=|usr=}}
| |
| − | {{tp|p=32586646|t=2020. Electrocardiographic features of patients with COVID-19 pneumonia.|pdf=|usr=}}
| |
| − | {{tp|p=32553587|t=2020. COVID-19 and hydroxychloroquine: Is the wonder drug failing?|pdf=|usr=}}
| |
| − | {{tp|p=32283298|t=2020. A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery.|pdf=|usr=}}
| |
| − | {{tp|p=32603692|t=2020. Current pharmacological treatments for SARS-COV-2: A narrative review.|pdf=|usr=}}
| |
| − | {{tp|p=32441761|t=2020. COVID-19 and QT interval prolongation: more than just drug toxicity?|pdf=|usr=}}
| |
| − | {{tp|p=26869865|t=2015. A systematic review of the cardiotoxicity of methadone.|pdf=|usr=}}
| |
| − | {{tp|p=32509013|t=2020. Glycyrrhizic acid exerts protective effects against hypoxia/reoxygenation-induced human coronary artery endothelial cell damage by regulating mitochondria.|pdf=|usr=}}
| |
| − | {{tp|p=21736423|t=2011. Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy.|pdf=|usr=}}
| |
| − | {{tp|p=25494485|t=2015. Cardiac risks associated with antibiotics: azithromycin and levofloxacin.|pdf=|usr=}}
| |
| − | {{tp|p=32350928|t=2020. Rethinking the role of hydroxychloroquine in the treatment of COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=29162702|t=2018. Structural basis for the antiarrhythmic blockade of a potassium channel with a small molecule.|pdf=|usr=}}
| |
| − | {{tp|p=32707160|t=2020. An overview of safety assessment of the medicines currently used in the treatment of COVID-19 disease.|pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32432127|t=2020. COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2.|pdf=|usr=}}
| |
| − | {{tp|p=26798623|t=2015. Long QT Syndrome: An Emerging Role for Inflammation and Immunity.|pdf=|usr=}}
| |
| − | {{tp|p=30294301|t=2018. Vitamin D Toxicity-A Clinical Perspective.|pdf=|usr=}}
| |
| − | {{tp|p=30532765|t=2018. FGF10 Protects Against Renal Ischemia/Reperfusion Injury by Regulating Autophagy and Inflammatory Signaling.|pdf=|usr=}}
| |
| − | {{tp|p=32733488|t=2020. Potential Fast COVID-19 Containment With Trehalose.|pdf=|usr=}}
| |
| − | {{tp|p=32733448|t=2020. Role of Autophagy in Lung Inflammation.|pdf=|usr=}}
| |
| − | {{tp|p=32574272|t=2020. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?|pdf=|usr=}}
| |
| − | {{tp|p=29632529|t=2018. Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?|pdf=|usr=}}
| |
| − | {{tp|p=32733907|t=2020. Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32426364|t=2020. Hydroxychloroquine: A Familiar Agent to Combat the Pandemic of COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32391371|t=2020. SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment.|pdf=|usr=}}
| |
| − | {{tp|p=32391370|t=2020. The Role of Hydroxychloroquine in Coronavirus Disease 2019. A Versatile Tool at the Service of Humanity.|pdf=|usr=}}
| |
| − | {{tp|p=31481873|t=2019. Hydrogen Sulfide Inhibits High Glucose-Induced Neuronal Senescence by Improving Autophagic Flux via Up-regulation of SIRT1.|pdf=|usr=}}
| |
| − | {{tp|p=31427967|t=2019. Hydroxychloroquine Improves Obesity-Associated Insulin Resistance and Hepatic Steatosis by Regulating Lipid Metabolism.|pdf=|usr=}}
| |
| − | {{tp|p=29184497|t=2017. Novel Two-Step Classifier for Torsades de Pointes Risk Stratification from Direct Features.|pdf=|usr=}}
| |
| − | {{tp|p=31636573|t=2019. Enhancing Autophagy Diminishes Aberrant Ca(2+) Homeostasis and Arrhythmogenesis in Aging Rabbit Hearts.|pdf=|usr=}}
| |
| − | {{tp|p=29527175|t=2018. Cardiac Arrhythmias and Antiarrhythmic Drugs: An Autophagic Perspective.|pdf=|usr=}}
| |
| − | {{tp|p=25221519|t=2014. Inward rectifiers and their regulation by endogenous polyamines.|pdf=|usr=}}
| |
| − | {{tp|p=32615807|t=2020. Sudden cardiac death in COVID-19 patients, a report of three cases.|pdf=|usr=}}
| |
| − | {{tp|p=20543968|t=2010. Small-molecule modulators of inward rectifier K+ channels: recent advances and future possibilities.|pdf=|usr=}}
| |
| − | {{tp|p=32470824|t=2020. Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement.|pdf=|usr=}}
| |
| − | {{tp|p=14594906|t=2003. Drug induced QT prolongation and torsades de pointes.|pdf=|usr=}}
| |
| − | {{tp|p=32387247|t=2020. Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019.|pdf=|usr=}}
| |
| − | {{tp|p=32387246|t=2020. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management.|pdf=|usr=}}
| |
| − | {{tp|p=32380291|t=2020. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.|pdf=|usr=}}
| |
| − | {{tp|p=32479900|t=2020. Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32470627|t=2020. COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=32407884|t=2020. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.|pdf=|usr=}}
| |
| − | {{tp|p=32438018|t=2020. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.|pdf=|usr=}}
| |
| − | {{tp|p=32244059|t=2020. SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes.|pdf=|usr=}}
| |
| − | {{tp|p=32585191|t=2020. COVID-19 and cardiac arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=26025323|t=2015. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential.|pdf=|usr=}}
| |
| − | {{tp|p=32676695|t=2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.|pdf=|usr=}}
| |
| − | {{tp|p=32695719|t=2020. Hydroxychloroquine in Dermatology and Beyond: Recent Update.|pdf=|usr=}}
| |
| − | {{tp|p=32534688|t=2020. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.|pdf=|usr=}}
| |
| − | {{tp|p=32462545|t=2020. Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review.|pdf=|usr=}}
| |
| − | {{tp|p=32389720|t=2020. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin.|pdf=|usr=}}
| |
| − | {{tp|p=32305588|t=2020. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.|pdf=|usr=}}
| |
| − | {{tp|p=32629115|t=2020. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?|pdf=|usr=}}
| |
| − | {{tp|p=32738307|t=2020. Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32687949|t=2020. Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal.|pdf=|usr=}}
| |
| − | {{tp|p=32674929|t=2020. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?|pdf=|usr=}}
| |
| − | {{tp|p=32205204|t=2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.|pdf=|usr=}}
| |
| − | {{tp|p=32565195|t=2020. Cardiac effects and toxicity of chloroquine: a short update.|pdf=|usr=}}
| |
| − | {{tp|p=32534189|t=2020. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.|pdf=|usr=}}
| |
| − | {{tp|p=32522674|t=2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32450198|t=2020. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.|pdf=|usr=}}
| |
| − | {{tp|p=32194152|t=2020. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.|pdf=|usr=}}
| |
| − | {{tp|p=32473921|t=2020. Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research.|pdf=|usr=}}
| |
| − | {{tp|p=30222237|t=2018. Incidence and outcomes of long QTc in acute medical admissions.|pdf=|usr=}}
| |
| − | {{tp|p=24403843|t=2013. Antibiotics for the treatment of rheumatoid arthritis.|pdf=|usr=}}
| |
| − | {{tp|p=32738490|t=2020. The continued dilemma about usage of Hydroxychloroquine: Respite is in randomized control trials.|pdf=|usr=}}
| |
| − | {{tp|p=30805547|t=2018. Electrocardiographic disturbances in children with systemic lupus erythematosus.|pdf=|usr=}}
| |
| − | {{tp|p=32281213|t=2020. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).|pdf=|usr=}}
| |
| − | {{tp|p=16984815|t=2006. Cell biology of membrane trafficking in human disease.|pdf=|usr=}}
| |
| − | {{tp|p=27803420|t=2016. Acquired Gitelman Syndrome in an Anti-SSA Antibody-positive Patient with a SLC12A3 Heterozygous Mutation.|pdf=|usr=}}
| |
| − | {{tp|p=20185054|t=2010. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.|pdf=|usr=}}
| |
| − | {{tp|p=27957082|t=2014. Use Of Rate And Rhythm Control Drugs In Patients Younger Than 65 Years With Atrial Fibrillation.|pdf=|usr=}}
| |
| − | {{tp|p=32270559|t=2020. Cardiac and arrhythmic complications in patients with COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32282502|t=2020. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19).|pdf=|usr=}}
| |
| − | {{tp|p=7204500|t=1981. Fate of plasma membrane during endocytosis. III. Evidence for incomplete breakdown of immunoglobulin in lysosomes of cultured fibroblasts.|pdf=|usr=}}
| |
| − | {{tp|p=28425222|t=2017. Class III antiarrhythmic drugs amiodarone and dronedarone impair KIR 2.1 backward trafficking.|pdf=|usr=}}
| |
| − | {{tp|p=32397558|t=2020. Impact of COVID-19 on the Cardiovascular System: A Review.|pdf=|usr=}}
| |
| − | {{tp|p=29581800|t=2018. Impact of Drug Induced Long QT Syndrome: A Systematic Review.|pdf=|usr=}}
| |
| − | {{tp|p=26865283|t=2016. Safety Concerns Surrounding Quinolone Use in Children.|pdf=|usr=}}
| |
| − | {{tp|p=31656203|t=2019. Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin.|pdf=|usr=}}
| |
| − | {{tp|p=32622008|t=2020. Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going.|pdf=|usr=}}
| |
| − | {{tp|p=27317161|t=2016. JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.|pdf=|usr=}}
| |
| − | {{tp|p=30515245|t=2018. Post-partum catastrophic antiphospholipid syndrome presenting with shock and digital ischaemia - A diagnostic and management challenge.|pdf=|usr=}}
| |
| − | {{tp|p=32494896|t=2020. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.|pdf=|usr=}}
| |
| − | {{tp|p=32654098|t=2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.|pdf=|usr=}}
| |
| − | {{tp|p=22239221|t=2012. Rational approaches to improving selectivity in drug design.|pdf=|usr=}}
| |
| − | {{tp|p=32514696|t=2020. Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic.|pdf=|usr=}}
| |
| − | {{tp|p=32356252|t=2020. COVID-19: Therapeutics and Their Toxicities.|pdf=|usr=}}
| |
| − | {{tp|p=26159649|t=2016. A Literature Review of the Use of Sodium Bicarbonate for the Treatment of QRS Widening.|pdf=|usr=}}
| |
| − | {{tp|p=18072176|t=2007. Case files of the Drexel University Medical Toxicology Fellowship: methadone-induced QTc prolongation.|pdf=|usr=}}
| |
| − | {{tp|p=29438998|t=2018. Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.|pdf=|usr=}}
| |
| − | {{tp|p=20498233|t=2010. A computational model of Purkinje fibre single cell electrophysiology: implications for the long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=10740988|t=2000. Antipsychotic agents and QT changes.|pdf=|usr=}}
| |
| − | {{tp|p=32642225|t=2020. Addressing the "What do we have to lose? Just give the drug" rationale: making the case for clinical trials and against off-label use in COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32363250|t=2020. Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Part 2: Potential Alternatives to the Use of Animals in Preclinical Trials.|pdf=|usr=}}
| |
| − | {{tp|p=32313885|t=2020. COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities.|pdf=|usr=}}
| |
| − | {{tp|p=32363351|t=2020. Takotsubo Syndrome in the Setting of COVID-19 Infection.|pdf=|usr=}}
| |
| − | {{tp|p=32703574|t=2020. Multilead QT Screening Is Necessary for QT Measurement: Implications for Management of Patients in the COVID-19 Era.|pdf=|usr=}}
| |
| − | {{tp|p=27042693|t=2016. STRUCTURAL AND FUNCTIONAL BASES OF CARDIAC FIBRILLATION. DIFFERENCES AND SIMILARITIES BETWEEN ATRIA AND VENTRICLES.|pdf=|usr=}}
| |
| − | {{tp|p=32356858|t=2020. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.|pdf=|usr=}}
| |
| − | {{tp|p=32278373|t=2020. Regulators split on antimalarials for COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32272080|t=2020. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations.|pdf=|usr=}}
| |
| − | {{tp|p=31925317|t=2020. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.|pdf=|usr=}}
| |
| − | {{tp|p=23864039|t=2013. Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease.|pdf=|usr=}}
| |
| − | {{tp|p=28079193|t=2016. ECG non-specific ST-T and QTc abnormalities in patients with systemic lupus erythematosus compared with rheumatoid arthritis.|pdf=|usr=}}
| |
| − | {{tp|p=25881046|t=2015. Comparison of azithromycin plus chloroquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children in Africa: a randomized, open-label study.|pdf=|usr=}}
| |
| − | {{tp|p=20003315|t=2009. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base.|pdf=|usr=}}
| |
| − | {{tp|p=18613962|t=2008. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials.|pdf=|usr=}}
| |
| − | {{tp|p=21628620|t=2011. Antiparasitic therapy.|pdf=|usr=}}
| |
| − | {{tp|p=10885139|t=1999. Malaria in American troops in the South and Southwest Pacific in World War II.|pdf=|usr=}}
| |
| − | {{tp|p=29315692|t=2018. Comprehensive review of cardiovascular toxicity of drugs and related agents.|pdf=|usr=}}
| |
| − | {{tp|p=25010388|t=2014. HMGB1 in health and disease.|pdf=|usr=}}
| |
| − | {{tp|p=32316270|t=2020. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.|pdf=|usr=}}
| |
| − | {{tp|p=29443946|t=2018. A Comparative Study of Human Saposins.|pdf=|usr=}}
| |
| − | {{tp|p=27869117|t=2016. Genome-wide RNAi screen reveals ALK1 mediates LDL uptake and transcytosis in endothelial cells.|pdf=|usr=}}
| |
| − | {{tp|p=23389616|t=2013. Malaria biology and disease pathogenesis: insights for new treatments.|pdf=|usr=}}
| |
| − | {{tp|p=32690910|t=2020. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives.|pdf=|usr=}}
| |
| − | {{tp|p=25533796|t=2015. Cardiorheumatology: cardiac involvement in systemic rheumatic disease.|pdf=|usr=}}
| |
| − | {{tp|p=19347024|t=2009. Diagnosis and management of the neurological complications of falciparum malaria.|pdf=|usr=}}
| |
| − | {{tp|p=32430617|t=2020. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).|pdf=|usr=}}
| |
| − | {{tp|p=32671650|t=2020. SARS-CoV-2/COVID-19: a primer for cardiologists.|pdf=|usr=}}
| |
| − | {{tp|p=29434902|t=2018. Chloroquine exerts antitumor effects on NB4 acute promyelocytic leukemia cells and functions synergistically with arsenic trioxide.|pdf=|usr=}}
| |
| − | {{tp|p=23760395|t=2013. Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling.|pdf=|usr=}}
| |
| − | {{tp|p=23759954|t=2013. Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo.|pdf=|usr=}}
| |
| − | {{tp|p=32550240|t=2020. Azithromycin Should Not Be Used to Treat COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=19030406|t=2007. A primer of paediatric toxic syndromes or 'toxidromes'|pdf=|usr=}}
| |
| − | {{tp|p=C7378994|t=2020. Azithromycin/hydroxychloroquine: Lengthening of the QT interval bradycardia and atrioventricular block following an off-label use: case report.|pdf=|usr=}}
| |
| − | {{tp|p=C7404419|t=ä. Communication missteps during COVIDâ€19 hurt those already most at risk.|pdf=|usr=}}
| |
| − | {{tp|p=C7334118|t=2020. Hydroxychloroquine: Corrected QT interval prolongation first degree atrioventricular block and left bundle branch block during an off-label treatment with hydroxychloroquine for COVID-19 pneumonia: 3 case reports.|pdf=|usr=}}
| |
| − | {{tp|p=C7334107|t=2020. Azithromycin/hydroxychloroquine: QT prolongation with a notched broad T-wave following off-label therapy: case report.|pdf=|usr=}}
| |
| − | {{tp|p=C7303435|t=2020. Azithromycin/hydroxychloroquine: Prolongation of the QT interval: case report.|pdf=|usr=}}
| |
| − | {{tp|p=C7290135|t=2020. QT interval prolongation with hydroxychloroquine plus azithromycin.|pdf=|usr=}}
| |
| − | {{tp|p=C7290151|t=2020. Risks of chloroquine or hydroxychloroquine use for COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=C7280102|t=ä. Effet bénéfique de l’association hydroxychloroquine/azithromycine dans le traitement des patients âgés atteints de la COVID-19 : résultats d’une étude observationnelle.|pdf=|usr=}}
| |
| − | {{tp|p=C7300994|t=2020. Meeting the Challenge: Keen oversight and flexible operations keep manufacturers viable and productive despite daunting business conditions.|pdf=|usr=}}
| |
| − | {{tp|p=C7272317|t=2020. Hydroxychloroquine- and azithromycin-related heart disorders.|pdf=|usr=}}
| |
| − | {{tp|p=C7256915|t=2020. Serious cardiac AEs with hydroxychloroquine during COVID-19 pandemic.|pdf=|usr=}}
| |
| − | {{tp|p=C7257351|t=ä. Surface Treatments to Enhance the Functionality of PPEs.|pdf=|usr=}}
| |
| − | {{tp|p=C7212241|t=2020. Hydroxychloroquine-associated QT interval prolongation.|pdf=|usr=}}
| |
| − | {{tp|p=C7197234|t=2020. Safety concerns with higher dosage chloroquine in COVID-19 patients.|pdf=|usr=}}
| |
| − | {{tp|p=C7197245|t=2020. Antimalarial use in COVID-19 patients requires close monitoring.|pdf=|usr=}}
| |
| − | {{tp|p=C7262183|t=2020. NAATP on telemedicine and a ‘disease of isolation’.|pdf=|usr=}}
| |
| − | {{tp|p=C7148702|t=2016. Tourism economics and policy analysis: Contributions and legacy of the Sustainable Tourism Cooperative Research Centre.|pdf=|usr=}}
| |
| − | {{tp|p=22737589|t=2011. Fungal genome resources at NCBI.|pdf=|usr=}}
| |
| − | {{tp|p=29308119|t=2013. CONTROLLED DELIVERY OF ANTIANGIOGENIC DRUG TO HUMAN EYE TISSUE USING A MEMS DEVICE.|pdf=|usr=}}
| |
| − | {{tp|p=21630127|t=2011. AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development.|pdf=|usr=}}
| |
| − | {{tp|p=16353918|t=2005. Population pharmacokinetics/pharmacodynamics of anesthetics.|pdf=|usr=}}
| |
| − | {{tp|p=14621961|t=2003. Passive and iontophoretic transport enhancement of insulin through porcine epidermis by depilatories: Permeability and fourier transform infrared spectroscopy studies.|pdf=|usr=}}
| |
| − | {{tp|p=C7124145|t=ä. Hospital Systems Management.|pdf=|usr=}}
| |
| − | {{tp|p=25308141|t=2014. Using Publication Metrics to Highlight Academic Productivity and Research Impact.|pdf=|usr=}}
| |
| − | {{tp|p=22435868|t=2012. Optimizing Clinical Operations as part of a Global Emergency Medicine Initiative in Kumasi Ghana: Application of Lean Manufacturing Principals to Low Resource Health Systems.|pdf=|usr=}}
| |
| − | {{tp|p=20370740|t=2010. Improving Child Protection in the Emergency Department: A Systematic Review of Professional Interventions for Health Care Providers.|pdf=|usr=}}
| |
| − | {{tp|p=27779508|t=2016. “Staying in the Gameâ€: How Procedural Variation Shapes Competence Judgments in Surgical Education.|pdf=|usr=}}
| |
| − | {{tp|p=26505105|t=2015. Thresholds of Principle and Preference: Exploring Procedural Variation in Postgraduate Surgical Education.|pdf=|usr=}}
| |
| − | {{tp|p=25250744|t=2014. What’s Behind the Scenes? Exploring the Unspoken Dimensions of Complex and Challenging Surgical Situations.|pdf=|usr=}}
| |
| − | {{tp|p=23969352|t=2013. Understanding Clinical Uncertainty: What Is Going on When Experienced Surgeons Are Not Sure What to Do?|pdf=|usr=}}
| |
| − | {{tp|p=32010761|t=2020. Academic E-Mail Overload and the Burden of “Academic Spamâ€.|pdf=|usr=}}
| |
| − | {{tp|p=20074982|t=2010. Comparison between population average and experimentally measured Arterial Input Function in predicting biopsy results in prostate cancer.|pdf=|usr=}}
| |
| − | {{tp|p=19515584|t=2009. Effect of the enhancement threshold on the computer-aided detection of breast cancer using MRI.|pdf=|usr=}}
| |
| − | {{tp|p=32022555|t=2020. Single Atom Dynamics in Chemical Reactions.|pdf=|usr=}}
| |
| − | {{tp|p=21545881|t=2011. The influence of novel compliant floors on balance control in elderly women—A biomechanical study.|pdf=|usr=}}
| |
| − | {{tp|p=19353388|t=2009. Supervisor-Student Relations: Examining the Spectrum of Conflicts of Interest in Bioscience Laboratories.|pdf=|usr=}}
| |
| − | {{tp|p=16467894|t=2005. Databases of Discovery.|pdf=|usr=}}
| |
| − | {{tp|p=14594412|t=2003. Estrogen plus progestin did not improve health-related quality of life in postmenopausal women 50 to 79 years of age.|pdf=|usr=}}
| |
| − | {{tp|p=29637764|t=2018. Surface-Anchored Metal–Organic Framework–Cotton Material for Tunable Antibacterial Copper Delivery.|pdf=|usr=}}
| |
| − | {{tp|p=31534827|t=2019. Effect of Ionic Liquid Modification on the ORR Performance and Degradation Mechanism of Trimetallic PtNiMo/C Catalysts.|pdf=|usr=}}
| |
| − | {{tp|p=30221028|t=2018. Tuning the Electrocatalytic Performance of Ionic Liquid Modified Pt Catalysts for the Oxygen Reduction Reaction via Cationic Chain Engineering.|pdf=|usr=}}
| |
| − | {{tp|p=32123740|t=2020. Synthesis of Phospho-Amino Acid Analogues as Tissue Adhesive Cement Additives.|pdf=|usr=}}
| |
| − | {{tp|p=29632885|t=2018. Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis.|pdf=|usr=}}
| |
| − | {{tp|p=28386601|t=2017. On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death.|pdf=|usr=}}
| |
| − | {{tp|p=25333917|t=2014. Reconstruction of cladoniamide biosynthesis reveals non-enzymatic routes to bisindole diversity.|pdf=|usr=}}
| |
| − | {{tp|p=22217014|t=2012. Inhibitors of Aminoglycoside Resistance Activated in Cells.|pdf=|usr=}}
| |
| − | {{tp|p=19278238|t=2009. Small Molecule Microarrays of RNA-Focused Peptoids Identifies Inhibitors of a Pathogenic Group I Intron RNA.|pdf=|usr=}}
| |
| − | {{tp|p=25695130|t=2015. A New Method To Image Heme-Fe Total Fe and Aggregated Protein Levels after Intracerebral Hemorrhage.|pdf=|usr=}}
| |
| − | {{tp|p=C7408243|t=2020. Ionic Liquid (1-Ethyl-3-methylimidazolium Acetate) Plasticization of Chitosan-Based Bionanocomposites.|pdf=|usr=}}
| |
| − | {{tp|p=32743155|t=2020. Waste-Printed Circuit Board Recycling: Focusing on Preparing Polymer Composites and Geopolymers.|pdf=|usr=}}
| |
| − | {{tp|p=32337441|t=2020. One-Pot Efficient Catalytic Oxidation for Bio-Vanillin Preparation and Carbon Isotope Analysis.|pdf=|usr=}}
| |
| − | {{tp|p=30613821|t=2018. Poly(glycerol sebacate)-Based Polyester–Polyether Copolymers and Their Semi-Interpenetrated Networks with Thermoplastic Poly(ester–ether) Elastomers: Preparation and Properties.|pdf=|usr=}}
| |
| − | {{tp|p=30411057|t=2018. iEDDA Conjugation Reaction in Radiometal Labeling of Peptides with 68Ga and 64Cu: Unexpected Findings.|pdf=|usr=}}
| |
| − | {{tp|p=30087946|t=2018. Challenges of Connecting Chemistry to Pharmacology: Perspectives from Curating the IUPHAR/BPS Guide to PHARMACOLOGY.|pdf=|usr=}}
| |
| − | {{tp|p=30023576|t=2017. Fluorescent and Photosensitizing Conjugates of Cell-Penetrating Peptide TAT(47-57): Design Microwave-Assisted Synthesis at 60 °C and Properties.|pdf=|usr=}}
| |
| − | {{tp|p=31457741|t=2017. Giant Enhancement of Carrier Mobility in Bimetallic Coordination Polymers.|pdf=|usr=}}
| |
| − | {{tp|p=31457533|t=2017. Low-Cost and High-Performance Hard Carbon Anode Materials for Sodium-Ion Batteries.|pdf=|usr=}}
| |
| − | {{tp|p=31457130|t=2016. Field-Induced Relaxation of Magnetization in a Three-Dimensional LnMOF with the Second Bridging Ligand Squarate.|pdf=|usr=}}
| |
| − | {{tp|p=29142789|t=2017. Catalytic Depolymerization of Lignin and Woody Biomass in Supercritical Ethanol: Influence of Reaction Temperature and Feedstock.|pdf=|usr=}}
| |
| − | {{tp|p=25548949|t=2015. EXPANSION OF BISINDOLE BIOSYNTHETIC PATHWAYS BY COMBINATORIAL CONSTRUCTION.|pdf=|usr=}}
| |
| − | {{tp|p=23656278|t=2012. Dimerization-Dependent Green and Yellow Fluorescent Proteins.|pdf=|usr=}}
| |
| − | {{tp|p=25328143|t=2015. Osteopontin is associated with inflammation and mortality in a mouse model of polymicrobial sepsis.|pdf=|usr=}}
| |
| − | {{tp|p=24773521|t=2014. Fatal injury caused by low-energy trauma – a 10-year rural cohort.|pdf=|usr=}}
| |
| − | {{tp|p=23284336|t=2012. Poly[aquaÂ(μ2-pyrimidine-2-carboxylÂato-κ4O N:O′ N′)(nitrato-κO)cadmium].|pdf=|usr=}}
| |
| − | {{tp|p=16511268|t=2006. Crystallization and preliminary X-ray diffraction analysis of a cold-adapted catalase from Vibrio salmonicida.|pdf=|usr=}}
| |
| − | {{tp|p=16508111|t=2005. Cloning preparation and preliminary crystallographic studies of penicillin V acylase autoproteolytic processing mutants.|pdf=|usr=}}
| |
| − | {{tp|p=18262230|t=2008. Hyalin is a Cell Adhesion Molecule Involved in Mediating Archenteron - Blastocoel Roof Attachment.|pdf=|usr=}}
| |
| − | {{tp|p=27708482|t=2016. Scientometric Dilemma: Is H-index Adequate for Scientific Validity of Academic’s Work?|pdf=|usr=}}
| |
| − | {{tp|p=25684846|t=2014. Factors Affecting Journal Quality Indicator in Scopus (SCImago Journal Rank) in Obstetrics and Gynecology Journals: a Longitudinal Study (1999-2013).|pdf=|usr=}}
| |
| − | {{tp|p=24825929|t=2014. Review of the Journal Acta Informatica Medica in 2013.|pdf=|usr=}}
| |
| − | {{tp|p=23572852|t=2013. Acta Informatica Medica Is Indexed In Pubmed And Archived In Pubmed Central.|pdf=|usr=}}
| |
| − | {{tp|p=23322957|t=2012. ON-LINE BIOMEDICAL DATABASES–THE BEST SOURCE FOR QUICK SEARCH OF THE SCIENTIFIC INFORMATION IN THE BIOMEDICINE.|pdf=|usr=}}
| |
| − | {{tp|p=27199537|t=2015. Imaging alterations in skeletal muscle channelopathies: a study in 15 patients.|pdf=|usr=}}
| |
| − | {{tp|p=22106717|t=2011. A novel N440K sodium channel mutation causes myotonia with exercise-induced weakness - exclusion of CLCN1 exon deletion/duplication by MLPA.|pdf=|usr=}}
| |
| − | {{tp|p=21314017|t=2010. State of the art in hereditary muscle channelopathies .|pdf=|usr=}}
| |
| − | {{tp|p=22029103|t=2010. Mendelian bases of myopathies cardiomyopathies and neuromyopathies.|pdf=|usr=}}
| |
| − | {{tp|p=29330575|t=2018. A new technique for minimal invasive complete spinal cord injury in minipigs.|pdf=|usr=}}
| |
| − | {{tp|p=26025657|t=2015. Dysregulated IGFBP5 expression causes axon degeneration and motoneuron loss in diabetic neuropathy.|pdf=|usr=}}
| |
| − | {{tp|p=22526019|t=2012. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.|pdf=|usr=}}
| |
| − | {{tp|p=27461056|t=2016. Impact of increased risk for fetal aneuploidy on maternal mood: a prospective longitudinal study.|pdf=|usr=}}
| |
| − | {{tp|p=30669911|t=2019. Clinical significance of cervical MRI in brachial plexus birth injury.|pdf=|usr=}}
| |
| − | {{tp|p=22553905|t=2012. Correlation between radiographic measures of acetabular morphology with 3D femoral head coverage in patients with acetabular retroversion.|pdf=|usr=}}
| |
| − | {{tp|p=20450421|t=2010. Correction of axial and rotational alignment after medial and lateral releases during balanced gap TKA: A clinical study of 54 patients.|pdf=|usr=}}
| |
| − | {{tp|p=18283583|t=2008. Cellular matrix and growth factor components of the joint capsule are modified early in the process of posttraumatic contracture formation in a rabbit model.|pdf=|usr=}}
| |
| − | {{tp|p=24644412|t=2014. EDITORIAL.|pdf=|usr=}}
| |
| − | {{tp|p=24453635|t=2013. EDITORIAL.|pdf=|usr=}}
| |
| − | {{tp|p=C7252145|t=ä. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model.|pdf=|usr=}}
| |
| − | {{tp|p=32528832|t=2020. Characterization of organic anion transporting polypeptide 1b2 knockout rats generated by CRISPR/Cas9: a novel model for drug transport and hyperbilirubinemia disease.|pdf=|usr=}}
| |
| − | {{tp|p=26579386|t=2014. Combined use of phospholipid complexes and self-emulsifying microemulsions for improving the oral absorption of a BCS class IV compound baicalin.|pdf=|usr=}}
| |
| − | {{tp|p=20644551|t=2010. Ferulic acid inhibits nitric oxide-induced apoptosis by enhancing GABAB1 receptor expression in transient focal cerebral ischemia in rats.|pdf=|usr=}}
| |
| − | {{tp|p=23033877|t=2013. Organization of the neural switching circuitry underlying reflex micturition.|pdf=|usr=}}
| |
| − | {{tp|p=26590876|t=2016. Pilot randomised trial of a brief intervention for comorbid substance misuse in psychiatric inâ€patient settings.|pdf=|usr=}}
| |
| − | {{tp|p=25891484|t=2015. Light therapy and serotonin transporter binding in the anterior cingulate and prefrontal cortex.|pdf=|usr=}}
| |
| − | {{tp|p=23350770|t=2013. Childhood catatonia autism and psychosis past and present: is there an ‘iron triangle’?|pdf=|usr=}}
| |
| − | {{tp|p=22150101|t=2012. Making childhood catatonia visible separate from competing diagnoses.|pdf=|usr=}}
| |
| − | {{tp|p=17244171|t=2007. Melancholia: restoration in psychiatric classification recommended.|pdf=|usr=}}
| |
| − | {{tp|p=12956826|t=2003. Postmaturity in a genetic subtype of schizophrenia.|pdf=|usr=}}
| |
| − | {{tp|p=9395159|t=1997. A comprehensive method of assessing routine CT scans in schizophrenia.|pdf=|usr=}}
| |
| − | {{tp|p=17280565|t=2007. The doctrine of the two depressions in historical perspective.|pdf=|usr=}}
| |
| − | {{tp|p=30666066|t=2018. The First Fifty Years of Acta Stomatologica Croatica (1966 - 2016): Citation Analysis.|pdf=|usr=}}
| |
| − | {{tp|p=30804605|t=2017. ACTIVITY WORKFLOW IN THE PROCESS OF ARTICLE PUBLICATION AND QUALITY CONTROL IN THE JOURNAL ACTA STOMATOLOGICA CROATICA.|pdf=|usr=}}
| |
| − | {{tp|p=27789906|t=2016. Acta stomatologica Croatica and PubMed Central.|pdf=|usr=}}
| |
| − | {{tp|p=18471796|t=2008. High Prevalence of Entamoeba moshkovskii in a Tanzanian HIV population.|pdf=|usr=}}
| |
| − | {{tp|p=29109130|t=2017. Effects of electroacupuncture at BL33 on detrusor smooth muscle activity in a rat model of urinary retention.|pdf=|usr=}}
| |
| − | {{tp|p=31723931|t=2019. Acute and Critical Care will be indexed in PubMed PubMed Central Emerging Sources Citation Index and Scopus.|pdf=|usr=}}
| |
| − | {{tp|p=26774820|t=2016. Negative urgency mediates the relationship between childhood maltreatment and problems with alcohol and cannabis in late adolescence.|pdf=|usr=}}
| |
| − | {{tp|p=25452074|t=2015. Development and psychometric properties of the Social Smoking Situations (S3) Scale: An enhanced measure of social exposure to smoking during adolescence.|pdf=|usr=}}
| |
| − | {{tp|p=24290209|t=2014. The effects of acute exercise on tobacco cravings and withdrawal symptoms in temporary abstinent pregnant smokers☆.|pdf=|usr=}}
| |
| − | {{tp|p=24183303|t=2014. Moderators of the Association Between Peer and Target Adolescent Substance Use.|pdf=|usr=}}
| |
| − | {{tp|p=18760878|t=2008. Nicotine dependence symptoms among young never-smokers exposed to secondhand tobacco smoke.|pdf=|usr=}}
| |
| − | {{tp|p=28429843|t=2018. Pooled analysis of three randomized double-blind placebo controlled trials with rimonabant for smoking cessation.|pdf=|usr=}}
| |
| − | {{tp|p=28317210|t=2017. Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: A respondent-driven sampling study.|pdf=|usr=}}
| |
| − | {{tp|p=24467265|t=2014. Association among different measures of alcohol use across adolescence and emerging adulthood.|pdf=|usr=}}
| |
| − | {{tp|p=24304295|t=2014. TESTING A SOCIAL ECOLOGICAL MODEL OF ALCOHOL USE: THE CALIFORNIA 50 CITY STUDY.|pdf=|usr=}}
| |
| − | {{tp|p=22296280|t=2012. Preferences for Evidence–Based Practice Dissemination in Addiction Agencies Serving Women: A Discrete–Choice Conjoint Experiment.|pdf=|usr=}}
| |
| − | {{tp|p=24977037|t=2012. Past Fame Present Frames and Future Flagship? An Exploration of How Health is Positioned in Canadian Foreign Policy.|pdf=|usr=}}
| |
| − | {{tp|p=23087490|t=2011. On the Nature and Strategies of Organized Interests in Health Care Policy Making.|pdf=|usr=}}
| |
| − | {{tp|p=28111591|t=2015. Delinquent behaviors among students exposed to family violence in Quebec schools.|pdf=|usr=}}
| |
| − | {{tp|p=28111592|t=2015. Health Outcomes of Sexual-Minority Youth in Canada: An Overview.|pdf=|usr=}}
| |
| − | {{tp|p=29177764|t=2018. ROCK and RHO Playlist for Preimplantation Development: Streaming to HIPPO Pathway and Apicobasal Polarity in the First Cell Differentiation.|pdf=|usr=}}
| |
| − | {{tp|p=23227044|t=2012. Do Peers See More in a Paper Than Its Authors?|pdf=|usr=}}
| |
| − | {{tp|p=20936175|t=2010. Designing Efficient Spaced Seeds for SOLiD Read Mapping.|pdf=|usr=}}
| |
| − | {{tp|p=20150956|t=2009. Synonymous Codon Usage Analysis of Thirty Two Mycobacteriophage Genomes.|pdf=|usr=}}
| |
| − | {{tp|p=26601093|t=2015. Potential risk factors associated with stress urinary incontinence among Iranian women.|pdf=|usr=}}
| |
| − | {{tp|p=24560216|t=2014. Comparison between the behavior of different hydrophobic peptides allowing membrane anchoring of proteins.|pdf=|usr=}}
| |
| − | {{tp|p=19233238|t=2009. Antioxidant Enzyme Gene Transfer for Ischemic Diseases.|pdf=|usr=}}
| |
| − | {{tp|p=28865027|t=2017. Drebrin and Spermatogenesis.|pdf=|usr=}}
| |
| − | {{tp|p=26002737|t=2015. Use of Chemical Auxiliaries to Control P450 Enzymes for Predictable Oxidations at Unactivated C–H Bonds of Substrates.|pdf=|usr=}}
| |
| − | {{tp|p=23955676|t=2014. Iatrogenic genetic damage of spermatozoa.|pdf=|usr=}}
| |
| − | {{tp|p=20384219|t=2010. Artificial Cell Microencapsulated Stem Cells in Regenerative Medicine Tissue Engineering and Cell Therapy.|pdf=|usr=}}
| |
| − | {{tp|p=29755309|t=2017. Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles.|pdf=|usr=}}
| |
| − | {{tp|p=18688288|t=2007. Multifunctional hydrogels that promote osteogenic hMSC differentiation through stimulation and sequestering of BMP2.|pdf=|usr=}}
| |
| − | {{tp|p=28116565|t=2017. Pulling together and pulling apart: influences of convergence and divergence on distributed healthcare teams.|pdf=|usr=}}
| |
| − | {{tp|p=21318045|t=2011. Recent Advances in the Pathobiology of Hodgkin s Lymphoma: Potential Impact on Diagnostic Predictive and Therapeutic Strategies.|pdf=|usr=}}
| |
| − | {{tp|p=31172125|t=2019. Demography of Medical Journals in Iran; a Cross-Sectional Study.|pdf=|usr=}}
| |
| − | {{tp|p=32551324|t=2020. Effectiveness in Bowel Cleansing and Patient Tolerability of Polyethylene Glycol versus Sodium Picosulphate in Patients Undergoing Colonoscopy.|pdf=|usr=}}
| |
| − | {{tp|p=31886452|t=2018. The Psychological Science Accelerator: Advancing Psychology through a Distributed Collaborative Network.|pdf=|usr=}}
| |
| − | {{tp|p=30775689|t=2018. Writing Empirical Articles: Transparency Reproducibility Clarity and Memorability.|pdf=|usr=}}
| |
| − | {{tp|p=30971863|t=2018. Multi-domain Causal Structure Learning in Linear Systems.|pdf=|usr=}}
| |
| − | {{tp|p=18486688|t=2008. Strain Theory of Malaria: The First 50 Years.|pdf=|usr=}}
| |
| − | {{tp|p=21907908|t=2011. Pharmacological Chaperones for Misfolded Gonadotropin-Releasing Hormone Receptors.|pdf=|usr=}}
| |
| − | {{tp|p=21081213|t=2010. The Cardiovascular Physiology and Pharmacology of Endothelin-1.|pdf=|usr=}}
| |
| − | {{tp|p=31637168|t=2019. Single Molecule Magnetism with Strong Magnetic Anisotropy and Enhanced Dy∙∙∙Dy Coupling in Three Isomers of Dyâ€Oxide Clusterfullerene Dy2O@C82.|pdf=|usr=}}
| |
| − | {{tp|p=29938193|t=2018. A Nacreâ€Like Carbon Nanotube Sheet for High Performance Liâ€Polysulfide Batteries with High Sulfur Loading.|pdf=|usr=}}
| |
| − | {{tp|p=31192867|t=2019. Use of Thermal Imaging to Identify Deep-Tissue Pressure Injury on Admission Reduces Clinical and Financial Burdens of Hospital-Acquired Pressure Injuries.|pdf=|usr=}}
| |
| − | {{tp|p=22400020|t=2012. Neurogenic Bladder.|pdf=|usr=}}
| |
| − | {{tp|p=24761357|t=2014. Clinical Trials Involving Biphasic Pulsed Current MicroCurrent and/or Low-Intensity Direct Current.|pdf=|usr=}}
| |
| − | {{tp|p=C7148074|t=ä. Ranking Significant Discrepancies in Clinical Reports.|pdf=|usr=}}
| |
| − | {{tp|p=C7148057|t=ä. DSR: A Collection for the Evaluation of Graded Disease-Symptom Relations.|pdf=|usr=}}
| |
| − | {{tp|p=22238503|t=2011. Satellite Remote Sensing for Developing Time and Space Resolved Estimates of Ambient Particulate in Cleveland OH.|pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=24309315|t=2011. Ionic channels as targets for drug design: a review on computational methods.|pdf=|usr=}}
| |
| − | {{tp|p=18693297|t=2008. Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients.|pdf=|usr=}}
| |
| − | {{tp|p=29921647|t=2018. Mechanisms and Drug Development in Atrial Fibrillation.|pdf=|usr=}}
| |
| − | {{tp|p=21079043|t=2010. Drug-induced long QT syndrome.|pdf=|usr=}}
| |
| − | {{tp|p=28720428|t=2017. Inhibitors of connexin and pannexin channels as potential therapeutics.|pdf=|usr=}}
| |
| − | {{tp|p=22274552|t=2012. Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury.|pdf=|usr=}}
| |
| − | {{tp|p=26660852|t=2016. KATP Channels in the Cardiovascular System.|pdf=|usr=}}
| |
| − | {{tp|p=32134952|t=2020. Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data.|pdf=|usr=}}
| |
| − | {{tp|p=25093754|t=2014. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial.|pdf=|usr=}}
| |
| − | {{tp|p=22087077|t=2011. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial.|pdf=|usr=}}
| |
| − | {{tp|p=30517121|t=2018. Subclinical parameters of arterial stiffness and arteriosclerosis correlate with QRISK3 in systemic lupus erythematosus.|pdf=|usr=}}
| |
| − | {{tp|p=27064990|t=2016. Relationship between QT Interval Length and Arterial Stiffness in Systemic Lupus Erythematosus (SLE): A Cross-Sectional Case-Control Study.|pdf=|usr=}}
| |
| − | {{tp|p=26296197|t=2015. Probucol-Induced alpha-Tocopherol Deficiency Protects Mice against Malaria Infection.|pdf=|usr=}}
| |
| − | {{tp|p=25793535|t=2015. Quinidine, but not eicosanoid antagonists or dexamethasone, protect the gut from platelet activating factor-induced vasoconstriction, edema and paralysis.|pdf=|usr=}}
| |
| − | {{tp|p=24205103|t=2013. AfroDb: a select highly potent and diverse natural product library from African medicinal plants.|pdf=|usr=}}
| |
| − | {{tp|p=22493697|t=2012. Cholesterol depletion in adipocytes causes caveolae collapse concomitant with proteosomal degradation of cavin-2 in a switch-like fashion.|pdf=|usr=}}
| |
| − | {{tp|p=19771169|t=2009. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.|pdf=|usr=}}
| |
| − | {{tp|p=27467575|t=2016. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.|pdf=|usr=}}
| |
| − | {{tp|p=26086192|t=2015. Targeting Human Transmission Biology for Malaria Elimination.|pdf=|usr=}}
| |
| − | {{tp|p=15811881|t=2005. Acute poisoning: understanding 90% of cases in a nutshell.|pdf=|usr=}}
| |
| − | {{tp|p=11009581|t=2000. QT prolongation due to roxithromycin.|pdf=|usr=}}
| |
| − | {{tp|p=432163|t=1979. Amiodarone in the treatment of refractory supraventricular and ventricular arrhythmias.|pdf=|usr=}}
| |
| − | {{tp|p=19287558|t=2008. Methadone-Associated QTc Prolongation: A Case Report and Review of the Literature.|pdf=|usr=}}
| |
| − | {{tp|p=10984545|t=2000. A common polymorphism associated with antibiotic-induced cardiac arrhythmia.|pdf=|usr=}}
| |
| − | {{tp|p=32425246|t=2020. Psychopharmacology of COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=31878817|t=2020. Acquired long QT syndrome in chronic kidney disease patients.|pdf=|usr=}}
| |
| − | {{tp|p=32409150|t=2020. An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.|pdf=|usr=}}
| |
| − | {{tp|p=32394513|t=2020. Chloroquine and hydroxychloroquine for COVID-19: A word of caution.|pdf=|usr=}}
| |
| − | {{tp|p=30858628|t=2019. Cardiac and vascular complications in rheumatoid arthritis.|pdf=|usr=}}
| |
| − | {{tp|p=30042604|t=2018. Antimalarials - are they effective and safe in rheumatic diseases?|pdf=|usr=}}
| |
| − | {{tp|p=32536565|t=2020. Living evidence in response to controversies about the use of antimalarials in COVID-19.|pdf=|usr=}}
| |
| − | {{tp|p=32493574|t=2020. COVID-19 and treatment guided by biochemical and molecular diagnostic tests to reduce myocardial damage and cardiotoxicity.|pdf=|usr=}}
| |
| − | {{tp|p=32638884|t=2020. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?|pdf=|usr=}}
| |
| − | {{tp|p=31953740|t=2020. Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study.|pdf=|usr=}}
| |
| − | {{tp|p=22953235|t=2012. Emerging zoonoses: the "one health approach".|pdf=|usr=}}
| |
| − | {{tp|p=30532635|t=2018. Prevalence of Torsades de Pointes inducing drugs usage among elderly outpatients in North Jordan Hospitals.|pdf=|usr=}}
| |
| − | {{tp|p=19563673|t=2009. Management of the critically poisoned patient.|pdf=|usr=}}
| |
| − | {{tp|p=24981420|t=2014. Natural small-molecule enhancers of autophagy induce autophagic cell death in apoptosis-defective cells.|pdf=|usr=}}
| |
| − | {{tp|p=23953801|t=2013. Extracellular potassium homeostasis: insights from hypokalemic periodic paralysis.|pdf=|usr=}}
| |
| − | {{tp|p=25630313|t=2014. Importance of QT interval in clinical practice.|pdf=|usr=}}
| |
| − | {{tp|p=32528194|t=2020. Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19.|pdf=|usr=}}
| |
| − | {{tp|p=7787469|t=1995. Use of amiodarone in the postmyocardial infarction patient.|pdf=|usr=}}
| |
| − | {{tp|p=25083239|t=2012. Drug-induced QT interval prolongation: mechanisms and clinical management.|pdf=|usr=}}
| |
| − | {{tp|p=25165550|t=2013. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.|pdf=|usr=}}
| |
| − | {{tp|p=25165548|t=2013. Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports.|pdf=|usr=}}
| |
| − | {{tp|p=29201344|t=2017. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature.|pdf=|usr=}}
| |
| − | {{tp|p=32368072|t=2020. Refractory Sarcoidosis: A Review.|pdf=|usr=}}
| |
| − | {{tp|p=30867824|t=2019. Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5.|pdf=|usr=}}
| |
| − | {{tp|p=32418730|t=2020. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.|pdf=|usr=}}
| |
| − | {{tp|p=32387694|t=2020. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.|pdf=|usr=}}
| |
| − | {{tp|p=32387409|t=2020. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.|pdf=|usr=}}
| |
| − | {{tp|p=32289548|t=2020. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.|pdf=|usr=}}
| |
| − | {{tp|p=32593867|t=2020. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.|pdf=|usr=}}
| |
| − | {{tp|p=30794895|t=2019. Drug repurposing for new, efficient, broad spectrum antivirals.|pdf=|usr=}}
| |
| − | {{tp|p=32726238|t=2020. Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.|pdf=|usr=}}
| |
| − | {{tp|p=23675554|t=2013. Drugs to be avoided in patients with long QT syndrome: Focus on the anaesthesiological management.|pdf=|usr=}}
| |
